<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">51093</article-id><article-id pub-id-type="doi">10.7554/eLife.51093</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Modulation of dopamine D<sub>1</sub> receptors via histamine H<sub>3</sub> receptors is a novel therapeutic target for Huntington's disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-158403"><name><surname>Moreno-Delgado</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-158401"><name><surname>Puigdellívol</surname><given-names>Mar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9955-3558</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" id="author-158364"><name><surname>Moreno</surname><given-names>Estefanía</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-189035"><name><surname>Rodríguez-Ruiz</surname><given-names>Mar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158405"><name><surname>Botta</surname><given-names>Joaquín</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6450-1267</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158404"><name><surname>Gasperini</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158361"><name><surname>Chiarlone</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158406"><name><surname>Howell</surname><given-names>Lesley A</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158402"><name><surname>Scarselli</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158362"><name><surname>Casadó</surname><given-names>Vicent</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158363"><name><surname>Cortés</surname><given-names>Antoni</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157878"><name><surname>Ferré</surname><given-names>Sergi</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41692"><name><surname>Guzmán</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-158365"><name><surname>Lluís</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-182385"><name><surname>Alberch</surname><given-names>Jordi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8684-2721</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157889"><name><surname>Canela</surname><given-names>Enric I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4992-7440</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-86248"><name><surname>Ginés</surname><given-names>Silvia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9479-8185</contrib-id><email>silviagines@ub.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-122325"><name><surname>McCormick</surname><given-names>Peter J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2225-5181</contrib-id><email>p.mccormick@qmul.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution>Department of Biomedical Science, Faculty of Medicine, University of Barcelona, Institut of Neuroscience</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution>Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution>School of Pharmacy, University of East Anglia, Norwich Research Park</institution><addr-line><named-content content-type="city">Norwich</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Department of Biochemistry and Molecular Biology I, School of Biology, Instituto Universitario de Investigación Neuroquímica, and Instituto Ramón y Cajal de Investigación Sanitaria, Complutense University of Madrid</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff7"><label>7</label><institution>School of Biological and Chemical Sciences, Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution>Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa</institution><addr-line><named-content content-type="city">Pisa</named-content></addr-line><country>Italy</country></aff><aff id="aff9"><label>9</label><institution>National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Aldrich</surname><given-names>Richard W</given-names></name><role>Senior Editor</role><aff><institution>The University of Texas at Austin</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>UCB BioPharma SPRL, Chemin de Foriest, Braine-l’Alleud, Braine-l'Alleud, Belgium</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>06</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e51093</elocation-id><history><date date-type="received" iso-8601-date="2019-08-14"><day>14</day><month>08</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-05-26"><day>26</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Moreno-Delgado et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Moreno-Delgado et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-51093-v2.pdf"/><abstract><p>Early Huntington’s disease (HD) include over-activation of dopamine D<sub>1</sub> receptors (D<sub>1</sub>R), producing an imbalance in dopaminergic neurotransmission and cell death. To reduce D<sub>1</sub>R over-activation, we present a strategy based on targeting complexes of D<sub>1</sub>R and histamine H<sub>3</sub> receptors (H<sub>3</sub>R). Using an HD mouse striatal cell model and HD mouse organotypic brain slices we found that D<sub>1</sub>R-induced cell death signaling and neuronal degeneration, are mitigated by an H<sub>3</sub>R antagonist. We demonstrate that the D<sub>1</sub>R-H<sub>3</sub>R heteromer is expressed in HD mice at early but not late stages of HD, correlating with HD progression. In accordance, we found this target expressed in human control subjects and low-grade HD patients. Finally, treatment of HD mice with an H<sub>3</sub>R antagonist prevented cognitive and motor learning deficits and the loss of heteromer expression. Taken together, our results indicate that D<sub>1</sub>R - H<sub>3</sub>R heteromers play a pivotal role in dopamine signaling and represent novel targets for treating HD.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>huntington's disease</kwd><kwd>dopamine</kwd><kwd>histamine</kwd><kwd>g-protein coupled receptors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>MRC</institution></institution-wrap></funding-source><award-id>MR/S022465/1</award-id><principal-award-recipient><name><surname>McCormick</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>RSC Grant Project</institution></institution-wrap></funding-source><award-id>RG140118</award-id><principal-award-recipient><name><surname>McCormick</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>BBSRC</institution></institution-wrap></funding-source><award-id>BB/N504282/3</award-id><principal-award-recipient><name><surname>McCormick</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economia y Competitividad</institution></institution-wrap></funding-source><award-id>RTI2018-094374-B-I00</award-id><principal-award-recipient><name><surname>Ginés</surname><given-names>Silvia</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008666</institution-id><institution>Fundació la Marató de TV3</institution></institution-wrap></funding-source><award-id>20140610</award-id><principal-award-recipient><name><surname>Canela</surname><given-names>Enric I</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007353</institution-id><institution>Jerome Lejeune Foundation</institution></institution-wrap></funding-source><award-id>FJL-01/01/2013</award-id><principal-award-recipient><name><surname>McCormick</surname><given-names>Peter J</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economia y Competitividad</institution></institution-wrap></funding-source><award-id>SAF2017-88076-R</award-id><principal-award-recipient><name><surname>Alberch</surname><given-names>Jordi</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Economia y Competitividad</institution></institution-wrap></funding-source><award-id>RTI2018-095311-B-I00</award-id><principal-award-recipient><name><surname>Guzmán</surname><given-names>Manuel</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>Supported by the intramural funds of the National Institute on Drug Abuse</award-id><principal-award-recipient><name><surname>Ferré</surname><given-names>Sergi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Progression of Huntington's disease can be slowed by altering dopamine signalling through the Dopamine 1 receptor - Histamine 3 receptor heteromer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Huntington’s disease (HD) is a dominant inherited progressive neurodegenerative disorder caused by expansion of a CAG repeat, coding a polyglutamine repeat within the <italic>N</italic>-terminal region of huntingtin protein (<xref ref-type="bibr" rid="bib56">Macdonald, 1993</xref>; <xref ref-type="bibr" rid="bib95">Vonsattel and DiFiglia, 1998</xref>). Although dysfunction and death of striatal medium-sized spiny neurons (MSSNs) is a key neuropathological hallmark of HD (<xref ref-type="bibr" rid="bib23">Ferrante et al., 1991</xref>; <xref ref-type="bibr" rid="bib94">Vonsattel et al., 1985</xref>), cognitive deficits appear long before the onset of motor disturbances (<xref ref-type="bibr" rid="bib48">Lawrence et al., 2000</xref>; <xref ref-type="bibr" rid="bib50">Lemiere et al., 2004</xref>). It has been postulated that alterations in the dopaminergic system may contribute to HD neuropathology (<xref ref-type="bibr" rid="bib15">Chen et al., 2013a</xref>; <xref ref-type="bibr" rid="bib41">Jakel and Maragos, 2000</xref>), as dopamine (DA) plays a key role in the control of coordinated movements. Increased DA levels and DA signaling occur at early stages of the disease (<xref ref-type="bibr" rid="bib15">Chen et al., 2013a</xref>; <xref ref-type="bibr" rid="bib27">Garret et al., 1992</xref>; <xref ref-type="bibr" rid="bib41">Jakel and Maragos, 2000</xref>), resulting in an imbalance in striatal neurotransmission initiating signaling cascades that may contribute to striatal cell death (<xref ref-type="bibr" rid="bib69">Paoletti et al., 2008</xref>; <xref ref-type="bibr" rid="bib79">Ross and Tabrizi, 2011</xref>). Several studies demonstrated that DA receptor antagonists and agents that decrease DA content reduce chorea and motor symptoms while dopaminergic stimulation exacerbate such symptoms (<xref ref-type="bibr" rid="bib40">Huntington Study Group, 2006</xref>; <xref ref-type="bibr" rid="bib59">Mestre et al., 2009</xref>; <xref ref-type="bibr" rid="bib89">Tang et al., 2007</xref>).</p><p>Within the striatum, two different MSSNs populations can be distinguished: 1) MSSNs expressing enkephalin and dopamine D<sub>2</sub> receptors (D<sub>2</sub>R), which give rise to the indirect striatal efferent pathway, and 2) MSSNs expressing substance P and dopamine D<sub>1</sub> receptors (D<sub>1</sub>R), comprising the direct striatal efferent pathway. Recently, several studies with experimental models have changed the traditional view that D<sub>2</sub>R-MSSNs are more vulnerable in HD (<xref ref-type="bibr" rid="bib11">Cepeda et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Kreitzer and Malenka, 2007</xref>), proposing a new view in which D<sub>1</sub>R-MSSNs are more vulnerable to the HD mutation. In this view, it has been demonstrated that mutant huntingtin enhances striatal cell death through the activation of D<sub>1</sub>R but not D<sub>2</sub>R (<xref ref-type="bibr" rid="bib69">Paoletti et al., 2008</xref>). More recently, it has been described that, at early stages of the disease, HD mice show an increase in glutamate release onto D<sub>1</sub>R neurons but not D<sub>2</sub>R neurons while, later in the disease, glutamate release is selectively decreased to D<sub>1</sub>R cells (<xref ref-type="bibr" rid="bib1">André et al., 2011a</xref>), indicating that several changes occur in D<sub>1</sub>R neurons at both early and late disease stages. Strategies that might reduce D<sub>1</sub>R signaling could prove successful towards preventing HD (<xref ref-type="bibr" rid="bib1">André et al., 2011a</xref>; <xref ref-type="bibr" rid="bib2">André et al., 2011b</xref>; <xref ref-type="bibr" rid="bib79">Ross and Tabrizi, 2011</xref>; <xref ref-type="bibr" rid="bib89">Tang et al., 2007</xref>). However, D<sub>1</sub>Rs are highly expressed in many tissues (<xref ref-type="bibr" rid="bib5">Beaulieu and Gainetdinov, 2011</xref>) and broad use of D<sub>1</sub>R antagonists as a preventive treatment has important drawbacks including locomotor impairments (<xref ref-type="bibr" rid="bib28">Giménez-Llort et al., 1997</xref>), or induce depression, parkinsonism and sedation in HD patients (<xref ref-type="bibr" rid="bib25">Frank et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Huntington Study Group, 2006</xref>).</p><p>Histamine is an important neuromodulator with four known G protein-coupled receptors (GPCRs). H<sub>3</sub>Rs are expressed in brain regions involved in both motor function (striatum) and cognition, such as the cortex, thalamus, hypothalamus, hippocampus and amygdala (<xref ref-type="bibr" rid="bib68">Panula and Nuutinen, 2013</xref>). It is known that in at least striatal GABAergic dynorphinergic neurons (<xref ref-type="bibr" rid="bib71">Pillot et al., 2002</xref>; <xref ref-type="bibr" rid="bib80">Ryu et al., 1994a</xref>; <xref ref-type="bibr" rid="bib81">Ryu et al., 1994b</xref>), both D<sub>1</sub>R and H<sub>3</sub>R are co-expressed and we and others have found that they establish functional negative interactions by forming molecular complexes termed heteromers (<xref ref-type="bibr" rid="bib63">Moreno et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Sánchez-Lemus and Arias-Montaño, 2004</xref>). Hence, in this work, we hypothesized that targeting D<sub>1</sub>R through these receptor complexes of D<sub>1</sub>R and H<sub>3</sub>R might serve as a more efficient and targeted strategy to slow the progression of HD. Specifically, we demonstrate that D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed and functional in early HD stages but are lost in late stages. An H<sub>3</sub>R antagonist acting through D<sub>1</sub>R-H<sub>3</sub>R heteromers acts as a protective agent against dopaminergic imbalance in early HD stages improving learning and long-term memory deficits and rescuing the loss of D<sub>1</sub>R-H<sub>3</sub>R complexes at late stages of HD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in wild type STHdh<sup>Q7</sup> and HD STHdh<sup>Q111</sup> striatal cell models</title><p>To test whether D<sub>1</sub>R-H<sub>3</sub>R heteromers could indeed be targets for controlling D<sub>1</sub>R signaling in HD, we first analyzed the expression of both receptors in immortalized striatal cells expressing endogenous levels of full-length wild-type STHdh<sup>Q7</sup> or mutant STHdh<sup>Q111</sup> huntingtin (<xref ref-type="bibr" rid="bib29">Ginés et al., 2010</xref>). Ligand binding determined that both STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells endogenously express similar levels of D<sub>1</sub>R and H<sub>3</sub>R (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). By proximity ligation assays (PLA), D<sub>1</sub>R-H<sub>3</sub>R heteromers were detected as red spots surrounding the blue stained nuclei in both cell types (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, left panels of both cell types) and in cells treated with control lentivirus vector (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) but not in cells depleted of H<sub>3</sub>R (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, right panels of both cell types) by shRNA, as shown by RT-PCR and functionality (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C</xref>), or in negative controls (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). To ensure that D<sub>1</sub>R-H<sub>3</sub>R heteromers were functional in STHdh cells, cell signaling experiments were performed. Using both STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells and concentrations of ligands previously shown to be optimal for receptor activation of the ERK1/2 pathway (<xref ref-type="bibr" rid="bib22">Ferrada et al., 2009</xref>; <xref ref-type="bibr" rid="bib64">Moreno et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Moreno et al., 2011</xref>), we observed that the D<sub>1</sub>R agonist SKF 81297 was able to increase ERK1/2 phosphorylation whereas it was prevented by D<sub>1</sub>R antagonist SCH 23390, and by the H<sub>3</sub>R antagonist thioperamide (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A,B</xref>) via cross-antagonism. In addition, we tested a previously described alternative signaling pathway activated downstream of D<sub>1</sub>R, Ca<sup>2+</sup> mobilization (<xref ref-type="bibr" rid="bib14">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib42">Jose et al., 1995</xref>). When cells were treated with the D<sub>1</sub>R agonist SKF 81297 a robust and rapid increase in cytosolic Ca<sup>2+</sup> was detected in both STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). Importantly, this calcium release could be dampened with the H<sub>3</sub>R antagonist thioperamide (cross-antagonism) (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). The above signaling data strongly support the presence of functional D<sub>1</sub>R-H<sub>3</sub>R heteromers in STHdh cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells.</title><p>PLA were performed in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells (<bold>A, D, F, H and J</bold>) or in cells infected with shH<sub>3</sub>R to silence H<sub>3</sub>R, observed as green stained cells due to the GFP expression included in the plasmid (<bold>A</bold>). D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized in STHdh cells as red spots around blue colored DAPI stained nucleus, but not in STHdh cells infected with shH<sub>3</sub>R vector (<bold>A</bold>). Calcium increases were measured in STHdh<sup>Q7</sup> (<bold>B, E and I</bold>) or STHdh<sup>Q111</sup> (<bold>C, G and K</bold>). Cells were treated (20 min) or not with the H<sub>3</sub>R antagonist thioperamide (10 μM) before the addition of vehicle or SKF 81297 (1 μM). In (<bold>D, E, F, G, H, I, J and K</bold>), STHdH<sup>Q7</sup> (<bold>D, E, H and I</bold>) or STHdH<sup>Q111</sup> (<bold>F, G, J and K</bold>) cells were also pre-treated for 60 min with 4 μM TM5 (<bold>D, E, F and G</bold>) or TM7 (<bold>H, I, J and K</bold>) peptides. Heteromers were visualized as red spots around DAPI (blue) stained nucleus in cells pre-treated with TM7 peptide. Scale: 20 μm. For each calcium curve values are expressed as a percentage increase with respect to untreated cells and are a mean ± SEM of 3 to 5 independent experiments. In (<bold>L and M</bold>), cell viability was determined in STHdh<sup>Q7</sup> (<bold>L</bold>) or STHdh<sup>Q111</sup> cells (<bold>M</bold>) pre-treated for 60 min with vehicle (white columns), with 4 μM TAT-TM7 (pale grey columns) or TAT-TM5 (grey columns) or infected with shH<sub>3</sub>R to silence H<sub>3</sub>R (dark grey columns) prior overstimulation with 30 μM SKF 81297. Values represent mean ± SEM (n = 24 to 30) of cell viability recovery expressed as in-fold respect to SKF 81297 treated cells. Student’s <italic>t</italic> test showed a significant (***p&lt;0.001) effect over SKF 81297 treated cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Negative controls for Proximity Ligation Assays (PLA) in striatal cells not depleted or H<sub>3</sub>R depleted by shRNA.</title><p>In (<bold>A</bold>), Proximity Ligation Assays (PLA) were performed in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells not H<sub>3</sub>R depleted but infected with GIPZ Non-silencing Lentiviral shRNA Control plasmid. D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized as red spots around blue colored DAPI stained nucleus (left panels), in infected cells stained in green due to the GFP expression included in the plasmid (middle panel). Merge images are given in the right panels. In (<bold>B</bold>), controls showing that H<sub>3</sub>R mRNA is not present in cells depleted of H<sub>3</sub>R by shRNA. STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells were not infected or infected with lentiviral silencing plasmid GIPZ Human histamine H3 receptor shRNA (shH<sub>3</sub>R). Values represent fold change respect to non-silencing vector. In (<bold>C</bold>) controls showing the lack of H<sub>3</sub>R stimulated signaling in cells depleted of H<sub>3</sub>R by shRNA. STHdh<sup>Q7</sup> or STHdh<sup>Q111</sup> cells were not stimulated (basal) or stimulated with the H<sub>3</sub>R agonist imetit (100 nM) and ERK 1/2 phosphorylation was determined. Values represent mean ± SEM (n = 3) of percentage of phosphorylation relative to basal levels found in untreated cells. Student’s <italic>t</italic> test showed significant differences over basal conditions (*p&lt;0.05, ***p&lt;0.001). In (<bold>D</bold>), PLA were performed in the absence of the D<sub>1</sub>R primary antibody using STHdh<sup>Q7</sup> or STHdh<sup>Q111</sup> cells not infected (left panels) or infected (right panels) with GIPZ Non-silencing Lentiviral shRNA Control plasmid. Scale bar: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>H<sub>3</sub>R ligands revert the D<sub>1</sub>R-mediated decreases in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cell viability.</title><p>STHdh<sup>Q7</sup> (<bold>A</bold>) or STHdh<sup>Q111</sup> (<bold>B</bold>) cells were treated for 20 min with vehicle, D<sub>1</sub>R antagonist SCH 23390 (1 μM) or the H<sub>3</sub>R antagonist thioperamide (1 μM) before the addition of SKF 81297 (100 nM) for an additional incubation period of 10 min and ERK 1/2 phosphorylation was determined. Values represent mean ± SEM (n = 3 to 4) of percentage of phosphorylation relative to basal levels found in untreated cells (control). One-way ANOVA followed by Bonferroni <italic>post hoc</italic> tests showed a significant effect over basal (***p&lt;0.001) or over SKF 81297 treatment (<sup>##</sup>p&lt;0.01). In (<bold>C, D</bold>), cell viability was determined in STHdh<sup>Q7</sup> (black curves) or STHdh<sup>Q111</sup> cells (red curves) pre-treated for 60 min with vehicle (<bold>C</bold>), or with the H<sub>3</sub>R antagonist thioperamide 10 μM (<bold>B</bold>) prior overstimulation with SKF 81297 (increasing concentrations in <bold>A</bold>) or 30 μM in <bold>B</bold>). Values represent mean ± SEM (n = 24 to 30) of percentage of viable cells respect to vehicle-treated cells (<bold>C</bold>) or the cell viability recovery expressed as in-fold respect to SKF 81297 treated cells (<bold>D</bold>). In (<bold>E and F</bold>) the effect of D<sub>1</sub>R antagonist, H<sub>3</sub>R antagonist and silencing vector transfection in striatal cells viability is shown. STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells were not infected (<bold>E</bold>) or infected (<bold>F</bold>) with GIPZ Non-silencing Lentiviral shRNA Control plasmid. Cells were pretreated for 60 min with vehicle, 10 μM SCH 23390 or 10 μM thioperamide prior over-stimulation with SKF 81297 (30 μM). Values represent mean ± SEM (n = 7 to 22) of percentage of viable cells respect to vehicle-treated cells (<bold>E</bold>) or the cell viability recovery expressed as in-fold respect to SKF 81297 treated cells (<bold>F</bold>). Student’s <italic>t</italic> test showed a significant (***p&lt;0.001) effect over not treated cells (<bold>E</bold>) or SKF 81297 treated cells (<bold>F</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Effect of low and high SKF 81297 concentrations in p-p38 and intracellular calcium release.</title><p>STHdh<sup>Q7</sup> (<bold>A and C</bold>) and STHdh<sup>Q111</sup> (<bold>B and D</bold>) cells were time-dependent stimulated with 1 μM or 30 μM SKF 81297 and intracellular calcium release (<bold>A and B</bold>) or p-p38 phosphorylation (<bold>C and D</bold>) was determined. In (<bold>A and B</bold>), curves are mean ± SEM of 3 to 6 independent experiments. In (<bold>C and D</bold>) values represent mean ± SEM of two independent experiments performed per triplicate of percentage of phosphorylation respect to vehicle-treated cells with example gels shown of STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> treated with 30 μM SKF 81297 below. Student’s <italic>t</italic> test showed a significant (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001) effect over not treated cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>H<sub>3</sub>R ligands revert the D<sub>1</sub>R-mediated decreases in cell viability in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> by modulating calcium signaling and p38 phosphorylation.</title><p>In (<bold>A and B</bold>), STHdh<sup>Q7</sup> (<bold>A</bold>) or STHdh<sup>Q111</sup> (<bold>B</bold>) cells were pre-treated for 20 min with vehicle or with the H<sub>3</sub>R antagonist thioperamide (10 μM) and were not stimulated or overstimulated with SKF 81297 (30 μM) prior intracellular calcium release determination. For each curve values are expressed as a percentage of increase with respect to untreated not overstimulated cells and are mean ± SEM of 3 to 9 independent experiments. In (<bold>C</bold>), STHdh<sup>Q7</sup> or STHdh<sup>Q111</sup> cells were treated for 20 min with medium (control), with SB 203580 (10 μM) or with the H<sub>3</sub>R antagonist thioperamide (10 μM). Cells were overstimulated with SKF 81297 (30 μM) and p38 phosphorylation was determined. Values represent mean ± SEM (n = 3) and are expressed as percentage over control. One-way ANOVA followed by Bonferroni <italic>post hoc</italic> tests showed a significant effect over control (**p&lt;0.01, ***p&lt;0.001) or over SKF 81297 treatment (<sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001). In (<bold>D</bold>), cell viability was determined in STHdh<sup>Q7</sup> (black curves) or STHdh<sup>Q111</sup> cells (red curves) pre-treated for 60 min with the p38 inhibitor SB 203580 prior overstimulation with SKF 81297 (30 μM). Values represent mean ± SEM (n = 24 to 30) of the cell viability recovery expressed as in-fold respect to SKF 81297 treated cells (<bold>D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>H<sub>3</sub>R ligands revert the D<sub>1</sub>R overstimulation-induced heteromer disruption in striatal cells.</title><p>Proximity Ligation Assays (PLA) were performed in STHdh<sup>Q7</sup> or STHdh<sup>Q111</sup> cells pre-treated for 60 min with vehicle or with the H<sub>3</sub>R antagonist thioperamide (10 µM) before addition of medium (in the case of the vehicle control) or SKF 81297 (30 μM, 45 min). D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized as red spots around blue colored DAPI stained nucleus in control and H<sub>3</sub>R ligands-treated cells, but not in SKF 81297 only treated cells. Scale bar: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig1-figsupp5-v2.tif"/></fig></fig-group><p>To further demonstrate that an H<sub>3</sub>R antagonist is dampening D<sub>1</sub>R activation involving D<sub>1</sub>R-H<sub>3</sub>R heteromers, we evaluated the effect of interfering peptides, which are synthetic peptides with the amino acid sequence of domains of the receptors involved in the heteromeric interface. This approach has been used by us and others to disrupt other heteromer complexes (<xref ref-type="bibr" rid="bib6">Bonaventura et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Guitart et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Hasbi et al., 2014</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib93">Viñals et al., 2015</xref>). In a previous study we showed the efficacy of this approach in demonstrating heteromerization of D<sub>1</sub>R with D<sub>3</sub>R, using a peptide with the sequence of D<sub>1</sub>R transmembrane domain 5 (TM5) but not TM7 (<xref ref-type="bibr" rid="bib35">Guitart et al., 2014</xref>). We therefore investigated whether synthetic peptides with the sequence of TM5, and TM7 (as a negative control) of D<sub>1</sub>R, fused to HIV-TAT, were also able to disrupt receptor D<sub>1</sub>R-H<sub>3</sub>R heteromers measured by PLA. In agreement with our hypothesis, there was a near complete loss in PLA fluorescence signal when STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells were incubated with TAT-TM five peptide (<xref ref-type="fig" rid="fig1">Figure 1D,F</xref>), but not for the negative control in which the TAT-TM seven peptide was used (<xref ref-type="fig" rid="fig1">Figure 1H,J</xref>). We next evaluated whether TM5 or TM7 would interfere with the observed cross-antagonism in calcium mobilization assays. Clearly, pretreatment of both STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells with the TAT-TM5 (<xref ref-type="fig" rid="fig1">Figure 1E,G</xref>) but not TAT-TM7 (<xref ref-type="fig" rid="fig1">Figure 1I,K</xref>) peptide disrupts the ability of the H<sub>3</sub>R antagonist thioperamide to dampen D<sub>1</sub>R calcium signaling. These results support that TM5 forms part of the interface of the D<sub>1</sub>R-H<sub>3</sub>R heteromer and demonstrate that the H<sub>3</sub>R antagonist effect is driven through direct interaction between D<sub>1</sub>R and H<sub>3</sub>R.</p></sec><sec id="s2-2"><title>H<sub>3</sub>R ligands prevent the D<sub>1</sub>R-induced cell death in STHdh<sup>Q7</sup> and STHd<sup>Q111</sup> cells</title><p>It has been previously reported that upon activation of D<sub>1</sub>R, STHdh cell viability is reduced (<xref ref-type="bibr" rid="bib69">Paoletti et al., 2008</xref>). To explore whether H<sub>3</sub>R ligands could impair D<sub>1</sub>R activation through D<sub>1</sub>R-H<sub>3</sub>R heteromers in a pathologically relevant readout, we used D<sub>1</sub>R-induced cell death as an output of D<sub>1</sub>R activation in STHdh cells. As expected, STHdh cell viability decreased when treated with the D<sub>1</sub>R agonist SKF 81297 in a concentration-dependent manner (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Significant cell death did not occur until 30 μM SKF 81297 was used (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>), an effect prevented by the D<sub>1</sub>R antagonist SCH 23390 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). Pre-treatment with the H<sub>3</sub>R antagonist thioperamide, which did not modify cell viability when administered alone (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>), increased the number of surviving cells in the presence of the D<sub>1</sub>R agonist SKF 81297 in both cell types (<xref ref-type="fig" rid="fig1">Figure 1L,M</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). Importantly, the effect of the H<sub>3</sub>R antagonist thioperamide was specific since no protection from D<sub>1</sub>R agonist-induced cell death was observed in cells depleted of H<sub>3</sub>R with shRNA lentiviral infection (<xref ref-type="fig" rid="fig1">Figure 1L,M</xref>), but was observed in cells transfected with the control lentivirus (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2F</xref>). In addition, we also demonstrated that recovery of viability induced by the H<sub>3</sub>R antagonist thioperamide was mediated by D<sub>1</sub>R-H<sub>3</sub>R heteromers since pre-incubation with D<sub>1</sub>R TM5 peptide, but not D<sub>1</sub>R TM7 impaired the H<sub>3</sub>R antagonist protection from D<sub>1</sub>R agonist-induced cell death (<xref ref-type="fig" rid="fig1">Figure 1L,M</xref>).</p><p>To better understand the mechanisms involved in D<sub>1</sub>R-H<sub>3</sub>R heteromer action, we determined which cellular signaling pathways are implicated in the cross-antagonism of H<sub>3</sub>R upon activation of D<sub>1</sub>R. Both concentrations of the D<sub>1</sub>R agonist SKF 81297, cytotoxic (30 µM) and non-cytotoxic (1 µM), can induce intracellular calcium release, which is more pronounced and persistent at 30 μM (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A,B</xref>). A correlation between the intensity of calcium responses and the activation of apoptotic pathways such as p38 (<xref ref-type="bibr" rid="bib84">Semenova et al., 2007</xref>) has been previously demonstrated. Thus, we measured changes in p38 phosphorylation levels using both concentrations of the D<sub>1</sub>R agonist SKF 81297 (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C,D</xref>). Interestingly, we found that increased phosphorylation of p38 only occurred at the cytotoxic concentration of SKF 81297. Similar to treatment with 1 μM SKF 81297 (see <xref ref-type="fig" rid="fig1">Figure 1</xref>), the calcium release induced by 30 μM SKF 81297 was also blocked by the H<sub>3</sub>R antagonist thioperamide (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A,B</xref>). Treatment with the H<sub>3</sub>R antagonist thioperamide reduced p38 phosphorylation upon D<sub>1</sub>R activation in both cell types (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>). Moreover, the p38 inhibitor SB 203580 blocked p38 phosphorylation (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>) and protected against the cytotoxic effect of the D<sub>1</sub>R agonist SKF 81297 in a dose-dependent manner (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4D</xref>), confirming that p38 is a key pathway involved in D<sub>1</sub>R-mediated cell death in these cells.</p><p>It has been reported that ligands can influence receptor oligomerization. To understand how the ligands used here might impact D<sub>1</sub>R-H<sub>3</sub>R heteromers we performed PLA after treating with either vehicle, SKF 81297 or SKF 81297 and thioperamide. We found that SKF 81297-induced a loss of PLA staining in both STHdh cells (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>), while pre-treatment with the H<sub>3</sub>R antagonist thioperamide preserved the number of punctate PLA spots (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p></sec><sec id="s2-3"><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in wild-type Hdh<sup>Q7/Q7</sup> and in Hdh<sup>Q7/Q111</sup> mutant knock-in mice at early but not late HD stages</title><p>To test whether D<sub>1</sub>R-H<sub>3</sub>R heteromers can indeed be targets for treating HD, we investigated their expression and function in the striatum, cerebral cortex and hippocampus of a widely accepted preclinical model of HD, the heterozygous Hdh<sup>Q7/Q111</sup> mutant knock-in mice, and their wild-type Hdh<sup>Q7/Q7</sup> littermates (<xref ref-type="bibr" rid="bib30">Giralt et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>). By PLA we confirmed that both Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice display D<sub>1</sub>R-H<sub>3</sub>R heteromers at 2 months (mo) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and four mo (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>) of age in all brain regions tested. No signal was observed in negative controls in which one of the PLA primary antibodies were missing (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Heteromer expression was similar in all brain areas and no differences were observed between genotypes at 4 mo of age (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Surprisingly, an almost complete loss of D<sub>1</sub>R-H<sub>3</sub>R heteromers was found in 6 mo and eight mo-old Hdh<sup>Q7/Q111</sup> mice but not in Hdh<sup>Q7/Q7</sup> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and <xref ref-type="fig" rid="fig3">Figure 3A,B</xref>), indicating that at more advanced disease stages the D<sub>1</sub>R-H<sub>3</sub>R heteromer is lost. Although at 8 mo of age we detected a partial decrease in striatal D<sub>1</sub>R expression in Hdh<sup>Q7/Q111</sup> compared with Hdh<sup>Q7/Q7</sup> mice using ligand binding experiments (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), the loss of heteromer expression is not due to a complete loss of receptor expression since by radioligand binding (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) and mRNA expression analysis (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) both receptors continue to be expressed.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in wild-type Hdh<sup>Q7/Q7</sup> and mutant Hdh<sup>Q7/Q111</sup> mice.</title><p>Striatal, cortical or hippocampal slices from 4-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were used. In (<bold>A</bold>), by Proximity Ligation Assays (PLA) D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized in all slices as green spots around blue colored DAPI stained nucleus. Scale bar: 20 μm. In (<bold>B</bold>), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data (% of positive cells or r) are the mean ± SEM of counts in 600–800 cells from 4 to 8 different fields from three different animals. Student’s <italic>t</italic> test showed no significant differences in heteromers expression in Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice. In (<bold>C</bold>), striatal, cortical or hippocampal organotypic slice cultures from 4-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were treated for 60 min with vehicle, the D<sub>1</sub>R antagonist SCH 23390 (10 μM) or H<sub>3</sub>R antagonist thioperamide (10 μM) before the addition of SKF 81297 (50 μM). After 48 h cell death was determined. Values represent mean ± SEM (n = 3 to 19) of percentage of cell death. One-way ANOVA followed by Bonferroni <italic>post hoc</italic> tests showed a significant effect over non-treated organotypic cultures (***p&lt;0.001) or of the H<sub>3</sub>R antagonist plus SKF 81297 treatment over the SKF 81297 (<sup>###</sup>p&lt;0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>D<sub>1</sub>R-H<sub>3</sub>R heteromer are expressed in 2-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice.</title><p>Proximity Ligation Assays (PLA) were performed using striatal, cortical or hippocampal slices from 2-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice. D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized in all slices as green spots around blue colored DAPI stained nucleus. Scale bar: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Negative controls for Proximity Ligation Assays (PLA) in mouse brain slices.</title><p>Proximity Ligation Assays (PLA) were performed in the absence of the primary antibody against D<sub>1</sub>R, using striatal, cortical or hippocampal slices from 4-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice. In all slices, a lack of green spots around blue colored DAPI stained nucleus was observed. Scale bar: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig2-figsupp2-v2.tif"/></fig></fig-group><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in wild-type Hdh<sup>Q7/Q7</sup> but not in 8-month-old mutant Hdh<sup>Q7/Q111</sup> mice.</title><p>Striatal, cortical or hippocampal slices from 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were used. In (<bold>A</bold>), by Proximity Ligation Assays (PLA) D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized in Hdh<sup>Q7/Q7</sup> mice but not in Hdh<sup>Q7/Q111</sup> mice as green spots around blue colored DAPI stained nucleus. Scale bar: 20 μm. In (<bold>B</bold>), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data (% of positive cells or r) are the mean ± SEM of counts in 600–800 cells from 5 to 7 different fields from three different animals. Student’s <italic>t</italic> test showed a significant (***p&lt;0.05) decrease of heteromers expression in Hdh<sup>Q7/Q111</sup> mice compared to the respective Hdh<sup>Q7/Q7</sup> mice. In (<bold>C</bold>) striatal, cortical or hippocampal organotypic slice cultures from 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were treated for 60 min with medium, the D<sub>1</sub>R antagonist SCH 23390 (10 μM) or the H<sub>3</sub>R antagonist thioperamide (10 μM) before the addition of SKF 81297 (50 μM) and cell death was determined. Values represent mean ± SEM (n = 3 to 6) of percentage of cell death. One-way ANOVA followed by Bonferroni <italic>post hoc</italic> tests showed a significant effect over non-treated organotypic cultures (*p&lt;0.05) or of the H<sub>3</sub>R antagonist plus SKF 81297 treatment over the SKF 81297 (<sup>#</sup>p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Expression of D<sub>1</sub>R-H<sub>3</sub>R heteromers in 6-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice chronically treated with saline.</title><p>In (<bold>A</bold>), Proximity Ligation Assays (PLA) were performed in striatal, cortical and hippocampal slices from 6-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice treated with saline. D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized as green spots around blue colored DAPI stained nucleus in Hdh<sup>Q7/Q7</sup> mice but not in Hdh<sup>Q7/Q111</sup> mice chronically treated with saline. Scale bar: 20 μm. In (<bold>B</bold>), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data (% of positive cells or r) are the mean ± SEM of counts in 600–800 cells from 4 to 8 different fields from three different animals. Student’s <italic>t</italic> test showed significant differences in D<sub>1</sub>R-H<sub>3</sub>R heteromer expression (***p&lt;0.001) compared to the respective Hdh<sup>Q7/Q7</sup> mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To test the role of D<sub>1</sub>R-H<sub>3</sub>R heteromers, organotypic mouse striatal, cortical and hippocampal cultures were obtained. Cell death was induced by the D<sub>1</sub>R agonist SKF 81297 (50 µM), and analysis of DAPI and propidium iodide staining was performed. As expected, D<sub>1</sub>R agonist SKF 81297 treatment increased the percentage of cell death in all three regions compared to vehicle-treated organotypic cultures without significant differences between genotypes at 4 mo of age (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Importantly, slices pre-treated with the H<sub>3</sub>R antagonist thioperamide, that does not modify cell death when administered alone, protected cells from D<sub>1</sub>R elicited cell death in an equivalent manner to the D<sub>1</sub>R antagonist SCH 23390 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), indicating that functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in different brain areas of Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice at early disease stages. The dramatic change in heteromer expression in eight mo-old Hdh<sup>Q7/Q111</sup> mice was mirrored by the lack of protection of the H<sub>3</sub>R antagonist thioperamide against SKF 81297-induced cell death in organotypic cultures (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), corroborating that the presence of D<sub>1</sub>R-H<sub>3</sub>R heteromers is needed for the H<sub>3</sub>R antagonist to prevent D<sub>1</sub>R-mediated cell death.</p></sec><sec id="s2-4"><title>Treatment with thioperamide prevents cognitive and motor learning deficits at early disease stages</title><p>To test whether the H<sub>3</sub>R antagonist thioperamide can exert beneficial effects in the initial stages of the disease we evaluated the effect of chronic thioperamide treatment on motor learning and memory deficits in mutant Hdh<sup>Q7/Q111</sup> mice. Since cognitive decline is observed in these HD mice from 6 mo of age (<xref ref-type="bibr" rid="bib7">Brito et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Giralt et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>) and the D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed and functional until the age of 5 mo (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>), we chose 5mo-old animals to start the thioperamide treatment (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Corticostriatal function in saline and thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice was analyzed by using the accelerating rotarod task that evaluates the acquisition of new motor skills (<xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>). Saline-treated mutant Hdh<sup>Q7/Q111</sup> mice were unable to maintain their balance on the rotarod as wild-type Hdh<sup>Q7/Q7</sup> mice revealing impaired acquisition of new motor skills (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Chronic treatment with thioperamide completely rescued motor learning deficits in mutant Hdh<sup>Q7/Q111</sup> mice as evidenced by a similar latency to fall in the accelerating rotarod as wild-type Hdh<sup>Q7/Q7</sup> mice. Next, recognition long-term memory (LTM) was analyzed by using the novel object recognition test (NORT) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). After two days of habituation in the open field arena (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), no significant differences were found between genotypes and/or treatments, demonstrating no alterations in motivation, anxiety or spontaneous locomotor activity. After habituation, animals were subjected to a training session in the open field arena in the presence of two similar objects (A and A’). Both saline and thioperamide-treated wild-type Hdh<sup>Q7/Q7</sup> and mutant Hdh<sup>Q7/Q111</sup> mice similarly explored both objects indicating neither object nor place preferences (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). After 24 hr, LTM was evaluated by changing one of the old objects (A’) for a novel one (B). Whereas saline-treated Hdh<sup>Q7/Q111</sup> mice did not show any preference for the novel object with respect to the familiar one, indicating recognition LTM deficits, thioperamide treatment completely prevented this LTM deficit in mutant Hdh<sup>Q7/Q111</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Next, spatial LTM was analyzed using the T-maze spontaneous alternation task (T-SAT) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). During the training, similar exploration time (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, left panel) and similar number of arm entries (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>, <italic>left panel</italic>) were found in all genotypes and treatments. After 5 hr, a testing session showed that saline-treated Hdh<sup>Q7/Q111</sup> mice had no preferences between the novel arm and the old arm, indicating spatial LTM deficits (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, right panel). Interestingly, mutant Hdh<sup>Q7/Q111</sup> mice treated with thioperamide spent more time in the novel <italic>versus</italic> the old arm, revealing preserved LTM (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, right panel). Overall, these data demonstrate the effectiveness of thioperamide treatment in restoring motor learning and preventing spatial and recognition LTM deficits in mutant Hdh<sup>Q7/Q111</sup> mice.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Thioperamide chronic treatment prevents motor learning, long-term memory (LTM) deficits and the loss of receptor heteromerization in 6-month-old Hdh<sup>Q7/Q111</sup> mice.</title><p>In (<bold>A</bold>), curves illustrating the latency to fall in the accelerating rotarod of 6-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice treated with saline or thioperamide from 5 months of age are shown. In (<bold>B</bold>), the exploration time for saline or thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice during the training and the testing (24 hr delay, LTM) sessions in a novel-object recognition task showing that long-term recognition memory deficits are rescued in the thioperamide-treated Hdh<sup>Q7/Q111</sup> mice. One-way ANOVA with Bonferroni <italic>post hoc</italic> showed significant differences (***p&lt;0.001) compared to the old object recognition. In (<bold>C</bold>), bar diagram illustrating the exploration time for saline- or thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice during the training and the 5 hr later testing in the T-SAT showing thioperamide reverses spatial long-term memory (LTM) deficits. In (<bold>A</bold>) to <bold>C</bold>), 11 saline-treated Hdh<sup>Q7/Q7</sup> mice, 10 thioperamide-treated Hdh<sup>Q7/Q7</sup> mice, seven saline-treated Hdh<sup>Q7/Q111</sup> mice and nine thioperamide-treated Hdh<sup>Q7/Q111</sup> mice were evaluated at 6 months of age. In (<bold>D</bold>) PLA were performed in striatal, cortical and hippocampal slices from 6-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice treated with thioperamide. D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized in all samples as green spots around blue colored DAPI stained nucleus. Scale bar: 20 μm. In (<bold>E</bold>) the right panel, the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data (% of positive cells or r) are the mean ± SEM of counts in 600–800 cells from 4 to 8 different fields from three different animals. Student’s <italic>t</italic> test showed no significant differences in heteromer expression in thioperamide-treated Hdh<sup>Q7/Q111</sup> mice compared to the respective Hdh<sup>Q7/Q7</sup> mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Functional D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in 5-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice.</title><p>Striatal (<bold>A</bold>) and cortical (<bold>B</bold>) organotypic slice cultures from 5-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were pre-treated for 60 min with vehicle, H<sub>3</sub>R antagonist thioperamide (10 μM), VUF5681 (10 μM) or D<sub>1</sub>R antagonist SCH 23390 (10 μM) before the addition of SKF 81297 (50 μM) and after 48 h cell death was determined. Values represent mean ± SEM (n = 5 to 8) of percentage of cell death. One-way ANOVA followed by Bonferroni <italic>post hoc</italic> tests showed a significant effect over vehicle treatment (***p&lt;0.001) or over SKF 81297 treated slices (###p&lt;0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Schematic representation of pharmacological treatments and behavioral analysis performed after chronic treatment with saline or thioperamide.</title><p>Three intraperitoneal injections per week of saline (NaCl 0.9% saline) or thioperamide (10 mg/Kg) were performed from 5-month-old to 8-month-old mice when the animals were sacrificed and perfused. Behavioral assessment started at 6 months of age with the evaluation of the ARTP, T-SAT, Open field and NORT. One cohort of animals was sacrificed and perfused 30 min after the last injection to evaluate PLA at 6 months of age. A second cohort of animals was sacrifice and perfused 30 min after the last injection to evaluate PLA at 8 months of age.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>No significant differences in the open field habituation were found between treatments and genotypes.</title><p>Motivation and anxiety differences between genotypes and treatments were analyzed by measuring the percentage of distance (<bold>A and E</bold>), the percentage of entries (<bold>B and F</bold>) and the percentage of time (<bold>C and G</bold>) between the periphery and the center in the open field arena at the first (<bold>A, B and C</bold>) or second (<bold>E, F and G</bold>) day of habituation in the open field arena. The spontaneous locomotor activity differences between genotypes and treatments were analyzed by measuring the total distance rove for each animal at first (<bold>D</bold>) or second (<bold>H</bold>) day of habituation in the open field arena. After two days of habituation in the open field arena, all mice behave equal. Data represents mean ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni <italic>post hoc</italic> comparisons; *p&lt;0.05, ***p&lt;0.001 compared to the periphery.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Training session in the T-SAT showed similar number of arm entries in all genotypes and treatments.</title><p>6-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice following the injection protocol in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> showed no differences in spontaneous locomotor activity or anxiogenic components in training sessions of the T-maze. 11 saline-treated Hdh<sup>Q7/Q7</sup> mice, 10 thioperamide-treated Hdh<sup>Q7/Q7</sup> mice, seven saline-treated Hdh<sup>Q7/Q111</sup> mice and nine thioperamide-treated Hdh<sup>Q7/Q111</sup> mice were evaluated. Data represents mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Expression of D<sub>1</sub>R-H<sub>3</sub>R heteromers in 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice chronically treated with thioperamide.</title><p>In (<bold>A</bold>), Proximity Ligation Assays (PLA), were performed in striatal, cortical and hippocampal slices. D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized as green spots around blue colored DAPI stained nucleus in 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice chronically treated with thioperamide. Scale bar: 20 μm. In (<bold>B</bold>), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data (% of positive cells or r) are the mean ± SEM of counts in 600–800 cells from 4 to 8 different fields from three different animals. Student’s <italic>t</italic> test showed no significant differences in D<sub>1</sub>R-H<sub>3</sub>R heteromer expression in thioperamide-treated Hdh<sup>Q7/Q111</sup> mice compared to the respective Hdh<sup>Q7/Q7</sup> mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig4-figsupp5-v2.tif"/></fig></fig-group><p>We next tested if the reversion of the HD phenotype in mutant Hdh<sup>Q7/Q111</sup> mice induced by thioperamide treatment correlated with the preservation of D<sub>1</sub>R-H<sub>3</sub>R heteromer expression. By PLA we observed that in saline-treated 6-mo-old Hdh<sup>Q7/Q111</sup> mice the heteromer expression was significantly diminished with respect to the age-matched Hdh<sup>Q7/Q7</sup> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). Notably, treatment with thioperamide significantly prevented the loss of D<sub>1</sub>R-H<sub>3</sub>R heteromers in all brain regions analyzed in Hdh<sup>Q7/Q111</sup> mice at both 6 (<xref ref-type="fig" rid="fig4">Figure 4D,E</xref>) and 8 mo of age (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A,B</xref>).</p></sec><sec id="s2-5"><title>Treatment with thioperamide ameliorates spinophilin-immunoreactive puncta alterations in the motor cortex and hippocampus of 6-month-old mutant Hdh<sup>Q7/Q111</sup> mice</title><p>Alterations in dendritic spine dynamics, density and morphology are critically involved in the synaptic deficits present in HD (<xref ref-type="bibr" rid="bib7">Brito et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Ferrante et al., 1991</xref>; <xref ref-type="bibr" rid="bib34">Guidetti et al., 2001</xref>; <xref ref-type="bibr" rid="bib55">Lynch et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Milnerwood et al., 2006</xref>; <xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Simmons et al., 2009</xref>; <xref ref-type="bibr" rid="bib86">Sotrel et al., 1993</xref>; <xref ref-type="bibr" rid="bib87">Spires et al., 2004</xref>). We recently described a significant decrease in dendritic spine density in the hippocampus (<xref ref-type="bibr" rid="bib7">Brito et al., 2014</xref>) and the motor cortex of mutant Hdh<sup>Q7/Q111</sup> mice (<xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>) without significant alterations in the striatum. To analyze whether the improvement of motor learning and memory deficits observed in thioperamide-treated mutant Hdh<sup>Q7/Q111</sup> mice was associated with a recovery in the density of dendritic spines, spinophilin immunostaining was performed in CA1 hippocampal and motor cortical coronal slices obtained from 6-mo-old wild-type Hdh<sup>Q7/Q7</sup> and mutant Hdh<sup>Q7/Q111</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). This methodology was used by us and others to identify structural alterations in dendritic spines (<xref ref-type="bibr" rid="bib37">Hao et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Tang et al., 2004</xref>). Confocal microscopy analyses revealed a significant reduction in the density of spinophilin-immunoreactive puncta in the <italic>stratum radiatum</italic> (apical dendrites of CA1 pyramidal neurons) and <italic>stratum oriens</italic> (basal dendrites of CA1 pyramidal neurons) of saline-treated 6-mo-old mutant Hdh<sup>Q7/Q111</sup> mice compared to saline-treated wild-type Hdh<sup>Q7/Q7</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Interestingly, thioperamide treatment prevented the decline in the number of spinophilin-immunoreactive puncta in mutant Hdh<sup>Q7/Q111</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Similar data was obtained when the layers of the motor cerebral cortex (M1) were analyzed. A significant reduction in the density of spinophilin-immunoreactive puncta in layer I and layer II-III, but not layer V, of the motor cortex of 6-mo-old saline-treated Hdh<sup>Q7/Q111</sup> mice was found compared to saline-treated Hdh<sup>Q7/Q7</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Interestingly, thioperamide-treated Hdh<sup>Q7/Q111</sup> mice exhibited a complete recovery in the density of spinophilin-immunoreactive puncta (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). No significant differences were found between groups when the mean size of spinophilin puncta was analyzed (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Altogether, these data demonstrate that the loss of spinophilin immunoreactive-puncta in mutant Hdh<sup>Q7/Q111</sup> mice can be ameliorated by thioperamide treatment.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Thioperamide treatment restored spinophilin-immunoreactive puncta reduction in the hippocampus and motor cortex of Hdh<sup>Q7/Q111</sup> mice and exerts no effect on the clearance of mutant huntingtin accumulation.</title><p>In (<bold>A</bold>) spinophilin-immunoreactive puncta were counted in the <italic>stratum oriens</italic> and <italic>stratum radiatum</italic> of CA1 hippocampus and in (<bold>B</bold>) layers I, II/III and V of motor cortex area 1 (M1) of saline and thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice. Quantitative analysis is shown as mean ± SEM (n = 9 images from three animals/group). Statistical analysis was performed using Student’s two-tailed <italic>t</italic> test. *p&lt;0.05, ***p&lt;0.001 compared to saline-treated Hdh<sup>Q7/Q7</sup> mice. #p&lt;0.05, ##p&lt;0.01, ###p&lt;0.001 compared to saline-treated Hdh<sup>Q7/Q111</sup> mice. In (<bold>C</bold>), Quantification of the protein levels of insoluble mHtt oligomeric forms and soluble mHtt forms of total striatal, hippocampal and cortical extracts from 6-month-old saline and thioperamide-treated Hdh<sup>Q7/Q111</sup> mice analysed by immunoblot. All histograms represent the mean ± SEM (n = 6–8 per group). Student’s <italic>t</italic> test showed no significant differences between groups.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Biochemical and Pathological Effects of Thioperamide treatment.</title><p>In (<bold>A</bold>), representative images showing spinophilin-immunoreactive puncta in the <italic>stratum oriens</italic> of CA1 hippocampus and in layer I of motor cortex area 1 (M1) of saline and thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice at 6 months of age. Quantitative analysis of the mean size of spinophilin-immunoreactive puncta in the <italic>stratum radiatum</italic> and <italic>stratum oriens</italic> of CA1 hippocampus and in layers I, II-III and V of motor cortex area 1 (M1) are shown as mean ± SEM (n = 9 images from three animals/group). Statistical analysis was performed using Student’s two-tailed <italic>t</italic> test. No significant differences were found. Scale bar: 5 μm. In (<bold>B</bold>), Representative western blots of total striatal, hippocampal and cortical extracts from 6-month-old saline and thioperamide-treated Hdh<sup>Q7/Q111</sup> mice. The blots were probed with 1C2 antibody for mutant huntingtin (mHtt). In samples from both saline and thioperamide-treated Hdh<sup>Q7/Q111</sup> mice insoluble oligomeric forms of mHtt were detected in the stacking gel and soluble forms were detected in the running gel.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig5-figsupp1-v2.tif"/></fig></fig-group><p>We also evaluated mutant huntingtin (mhtt) aggregates in the striatum, cerebral cortex and hippocampus of mutant Hdh<sup>Q7/Q111</sup> mice after saline or thioperamide treatment, as another pathological hallmark of HD (<xref ref-type="bibr" rid="bib3">Arrasate and Finkbeiner, 2012</xref>; <xref ref-type="bibr" rid="bib30">Giralt et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Hoffner et al., 2007</xref>). 1C2 immunostaining revealed in lysates from either vehicle or treated mutant Hdh<sup>Q7/Q111</sup> mice a substantial accumulation of mhtt oligomeric forms detected as a diffuse smear in the stacking gel (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Thioperamide treatment failed to prevent the accumulation of these oligomeric forms (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). No significant differences between groups were found when soluble monomeric mhtt levels were analyzed (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>).</p></sec><sec id="s2-6"><title>Thioperamide treatment does not rescue memory and motor learning deficits in mutant Hdh<sup>Q7/Q111</sup> mice when D<sub>1</sub>R-H<sub>3</sub>R heteromers are lost</title><p>If the behavioral improvements observed after thioperamide treatment are mediated by the D<sub>1</sub>R-H<sub>3</sub>R heteromer and not just by the blockade of the single H<sub>3</sub>R, then a treatment paradigm in the absence of the heteromer should have no effect. To test this hypothesis, we used wild-type Hdh<sup>Q7/Q7</sup> and mutant Hdh<sup>Q7/Q111</sup> mice at the age of 7 months, when we found the heteromer to be lost. Animals were chronically treated with saline or thioperamide for 1 month and motor learning was evaluated using the accelerating rotarod task. As expected, saline-Hdh<sup>Q7/Q111</sup> mice exhibited poor performance in this task showing shorter latency to fall compared to wild-type Hdh<sup>Q7/Q7</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Notably, thioperamide treatment had no effect on motor learning performance as both saline- and thioperamide-treated mutant Hdh<sup>Q7/Q111</sup> mice were indistinguishable demonstrated by similar latency to fall in the accelerating rotarod task (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Thioperamide chronic treatment does not prevent motor learning and long-term memory (LTM) deficits in 8-month-old Hdh<sup>Q7/Q111</sup> mice when the D<sub>1</sub>R-H<sub>3</sub>R heteromer is not expressed.</title><p>In (<bold>A</bold>), curves illustrating the latency to fall in the accelerating rotarod of 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice treated with saline or thioperamide from 7 months of age are shown. Two-way ANOVA with repeated measures showed significant differences (**p&lt;0.01) of saline-treated Hdh<sup>Q7/Q111</sup> mice compared to saline-treated Hdh<sup>Q7/Q7</sup> mice or (##p&lt;0.01) thioperamide-treated Hdh<sup>Q7/Q111</sup> mice compared to saline-treated Hdh<sup>Q7/Q7</sup> mice. 11 saline-treated Hdh<sup>Q7/Q7</sup> mice, 11 thioperamide-treated Hdh<sup>Q7/Q7</sup> mice, eight saline-treated Hdh<sup>Q7/Q111</sup> mice and nine thioperamide-treated Hdh<sup>Q7/Q111</sup> mice were evaluated at 8 months of age. In (<bold>B</bold>), bar diagram illustrating the exploration time for saline or thioperamide-treated Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice during the training and the testing (24 hr delay, LTM) sessions in a novel-object recognition task showing that long-term recognition memory deficits are not rescued in the thioperamide-treated Hdh<sup>Q7/Q111</sup> mice. One-way ANOVA with Bonferroni <italic>post hoc</italic> comparisons showed significant differences (***p&lt;0.001) compared to the old object recognition. 11 saline-treated Hdh<sup>Q7/Q7</sup> mice, 12 thioperamide-treated Hdh<sup>Q7/Q7</sup> mice, 10 saline-treated Hdh<sup>Q7/Q111</sup> mice and 11 thioperamide-treated Hdh<sup>Q7/Q111</sup> mice were evaluated at 8 months of age.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig6-v2.tif"/></fig><p>We next asked whether thioperamide treatment could improve cognitive function by rescuing memory deficits in these same animals. Saline-treated 8-mo-old Hdh<sup>Q7/Q111</sup> mice exhibited long-term memory deficits when recognition memory was analyzed using the novel object recognition test (NORT) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Similar to motor learning results, chronic treatment with thioperamide did not rescue Hdh<sup>Q7/Q111</sup> mice from memory deficits (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Overall, these results demonstrate that the effect of thioperamide in learning and memory in Hdh<sup>Q7/Q111</sup> mice requires the proper expression and function of D<sub>1</sub>R-H<sub>3</sub>R heteromers.</p></sec><sec id="s2-7"><title>D<sub>1</sub>R-H<sub>3</sub>R heteromer expression changes occur in other rodent HD models and in HD patients</title><p>The fact that thioperamide treatment 1) prevents cognitive and motor learning deficits, 2) ameliorates striatal neuropathology, 3) ameliorates morphological alterations and 4) prevents the loss of D<sub>1</sub>R-H<sub>3</sub>R heteromers at 6 mo and 8 mo of age in a mouse model of HD is suggestive that thioperamide, or a future pharmacologically improved H<sub>3</sub>R antagonist specifically targeting D<sub>1</sub>R-H<sub>3</sub>R heteromers, can be used to treat HD symptoms. To test this, we investigated D<sub>1</sub>R-H<sub>3</sub>R heteromer expression in other transgenic HD mouse models and in human caudate-putamen slices using PLA. The loss of heteromer expression compared with wild-type littermates was also observed in other mouse models of HD, the R6/1 and R6/2 mice transgenic for the human huntingtin exon 1 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A,B</xref>, respectively). Importantly, D<sub>1</sub>R-H<sub>3</sub>R heteromers were detected as green spots surrounding the blue stained nuclei in human caudate-putamen slices from control individuals and low-grade (grade 0, 1 and 2) HD patients (<xref ref-type="fig" rid="fig7">Figure 7A,B</xref>). In contrast, green spots were almost absent in samples from high-grade (grade 3 or grade 4) HD patients (<xref ref-type="fig" rid="fig7">Figure 7A,B</xref>). These results show that D<sub>1</sub>R-H<sub>3</sub>R heteromer formation changes during disease progression and, importantly, that humans express D<sub>1</sub>R-H<sub>3</sub>R heteromers at early disease stages.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Striatal D<sub>1</sub>R-H<sub>3</sub>R heteromers are expressed in human control subjects and grade 2 HD patients but not in grade 3–4 HD patients.</title><p>In (<bold>A</bold>), by Proximity Ligation Assays (PLA), D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized as green spots around blue colored DAPI stained nucleus in human striatal slices from age matched control subjects and 0–2 grade HD patients but not in 3–4 grade HD patients. Scale bar: 20 μm. In (<bold>B</bold>), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus). <italic>r values</italic> (number of green spots/cell containing spots) are shown above each bar. Data are mean ± SEM of counts in 600–800 cells from 10 different fields from subject described in Materials and Methods. Student’s <italic>t</italic> test showed a significant (***p&lt;0.001) decrease of heteromers expression in 3–4 grade HD patients compared to control subjects.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>D<sub>1</sub>R-H<sub>3</sub>R heteromer are not expressed in HD R6/1 and R6/2 mouse models.</title><p>Proximity Ligation Assays (PLA) were performed using striatal or cortical slices from age matched wild type littermates (WT) and 4-month-old R6/1 (<bold>A</bold>) or 8-week-old R6/2 mice (<bold>B</bold>). D<sub>1</sub>R-H<sub>3</sub>R heteromers were visualized only in wild-type mouse slices as green spots around blue colored DAPI stained nucleus. Scale bar: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51093-fig7-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The imbalance of dopamine inputs throughout HD progression represents a potential ‘point of no return’ for HD patients as this disequilibrium can eventually lead to substantial neuronal dysfunction and cell death. In the present study, we demonstrate that 1) excess dopamine signaling via D<sub>1</sub>R leads to cell death by activating the p38 pathway; 2) D<sub>1</sub>R-H<sub>3</sub>R complexes are found within the striatum, cortex and hippocampus of WT mice and in HD mice at early but not late disease stages; 3) targeting D<sub>1</sub>R via D<sub>1</sub>R-H<sub>3</sub>R complexes can slow progression of the disease in early but not late stages when the complexes are lost; and 4) D<sub>1</sub>R-H<sub>3</sub>R complexes are expressed in the human brain and thus represent potential therapeutic targets. This is the first demonstration of GPCR heteromers as potential targets to treat HD. Together, these data support a novel role for D<sub>1</sub>R-H<sub>3</sub>R complexes in neuroprotection and HD.</p><p>Several studies have revealed that dopamine neurotoxicity increases the sensitivity of MSSNs to glutamate inputs and leads to striatal neurodegeneration, a role ascribed to aberrant D<sub>1</sub>R and not D<sub>2</sub>R (<xref ref-type="bibr" rid="bib12">Cepeda and Levine, 1998</xref>; <xref ref-type="bibr" rid="bib24">Flores-Hernández et al., 2002</xref>; <xref ref-type="bibr" rid="bib69">Paoletti et al., 2008</xref>; <xref ref-type="bibr" rid="bib89">Tang et al., 2007</xref>). Thus, pharmacological treatments aimed to reduce D<sub>1</sub>R signaling may be beneficial to prevent or slow striatal cell death. Although we cannot rule out the participation of D<sub>2</sub>R in striatal degeneration, our results suggest that D<sub>1</sub>R is a major executor of the final signaling cascades that lead to cell death in HD. This is further supported by the fact that D<sub>1</sub>R is in excess over D<sub>2</sub>R in the striatum, so it is plausible that the former will be more significantly activated than the latter at increased DA levels. We have demonstrated that a toxic but not sub-toxic concentration of SKF81297 activates the p38 pro-apoptotic pathway, despite both concentrations triggering calcium release, albeit at different levels. Accordingly, p38 inhibitors completely abrogated the cell death induced by SKF81297 treatment, supporting the benefits of modulation of D<sub>1</sub>R signaling as potential treatment in HD. However, direct manipulation of DA production and/or D<sub>1</sub>R signalling via a specific antagonist has limited therapeutic ability due to associated deleterious side effects. An alternative approach is to modify D<sub>1</sub>R signalling via the histamine neuromodulator. An interaction between H<sub>3</sub>R and the dopaminergic system has been previously reported by us and others (<xref ref-type="bibr" rid="bib45">Kononoff Vanhanen et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Rapanelli et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Rapanelli et al., 2014</xref>). In this frame, we have demonstrated that H<sub>3</sub>R ligands completely abrogate striatal cell death induced by D<sub>1</sub>R, likely by inhibition of D<sub>1</sub>R-mediated calcium influx and p38 activation. Importantly, D<sub>1</sub>R-H<sub>3</sub>R complexes were found in the striatum, cortex and hippocampus from wild-type Hdh<sup>Q7/Q7</sup> and mutant Hdh<sup>Q7/Q111</sup> mice, regions known to be affected by mutant huntingtin toxicity (<xref ref-type="bibr" rid="bib76">Reiner et al., 1988</xref>; <xref ref-type="bibr" rid="bib78">Rosas et al., 2003</xref>; <xref ref-type="bibr" rid="bib95">Vonsattel and DiFiglia, 1998</xref>).</p><p>The mechanisms of action of D<sub>1</sub>R-H<sub>3</sub>R heteromers can be multiple including allosteric effects. Indeed, the efficacy of the disrupting peptides supports protein-protein-driven effects. A second and potentially additional mechanism is that heteromer formation may alter the trafficking of D<sub>1</sub>R, which could have pleiotropic consequences on signaling. For example it is known that overstimulation of D<sub>1</sub>R induces receptor internalization promoting rapid intracellular signaling (<xref ref-type="bibr" rid="bib46">Kotowski et al., 2011</xref>) and that receptor internalization can activate secondary signaling pathways (<xref ref-type="bibr" rid="bib53">Lohse and Calebiro, 2013</xref>). We observe in vitro that thioperamide treatment maintains the PLA signal while in vivo we see similar effects. The signaling effects we observe appears to be on a variety of concentrations and timescales in agreement with previous studies showing that GPCR signaling occurs with varied kinetics (<xref ref-type="bibr" rid="bib9">Calebiro et al., 2010a</xref>; <xref ref-type="bibr" rid="bib10">Calebiro et al., 2010b</xref>). Indeed, part of the concern of trying to target GPCR heteromers for therapeutic purposes is the uncertainty around their stability and thus indirectly whether they can impact GPCR signaling at every timescale. For the case of D<sub>1</sub>R-H<sub>3</sub>R heteromers, it appears that they are stable enough that they can affect both rapid receptor signaling (e.g., Ca<sup>2+</sup> mobilization) and longer cell signaling pathways like p38, two events that have previously been involved in neuronal cell death in HD (<xref ref-type="bibr" rid="bib17">Dau et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Fan et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Muller and Leavitt, 2014</xref>; <xref ref-type="bibr" rid="bib90">Taylor et al., 2013</xref>; <xref ref-type="bibr" rid="bib97">Wang et al., 2013</xref>). It is unclear what controls D<sub>1</sub>R-H<sub>3</sub>R heteromer formation or why it is lost during progression of HD. Whether it is a change in expression of an accessory protein, a post-translational modification or a change in cell physiology/morphology remains to be explored.</p><p>Our findings do not rule out that H<sub>3</sub>R ligands by targeting D<sub>2</sub>R-H<sub>3</sub>R heteromers (<xref ref-type="bibr" rid="bib21">Ferrada et al., 2008</xref>) could block D<sub>2</sub>R signaling and contribute to cell death protection. However, several findings argue in favor of D<sub>1</sub>R-H<sub>3</sub>R heteromer as uniquely responsible for the effects of thioperamide on cell death reduction. First, D<sub>1</sub>R over-activation induces cell death-related pathways and D<sub>1</sub>R-H<sub>3</sub>R disruption. In addition, pre-treatment with H<sub>3</sub>R ligands can block D<sub>1</sub>R-induced cell death and prevent D<sub>1</sub>R-H<sub>3</sub>R loss. Finally, the effect of TAT-peptide analogues of D<sub>1</sub>R transmembrane domains in D<sub>1</sub>R-H<sub>3</sub>R stability and function demonstrate that we are observing specific D<sub>1</sub>R-H<sub>3</sub>R, and not D<sub>2</sub>R-H<sub>3</sub>R, signaling and function. Thioperamide has recently been suggested to act via the H<sub>4</sub>R receptor. However, several pieces of our data suggest H<sub>4</sub>R is not responsible for the observed effects. First, we measured similar effects using VUF 5681, a different H<sub>3</sub>R antagonist. In addition we lose all effects of thioperamide in cells where H<sub>3</sub>R expression was silenced or when D<sub>1</sub>R-H<sub>3</sub>R heteromers are lost in the mice yet H<sub>4</sub>R should still be expressed. Finally, H<sub>4</sub>R is thought to be mainly expressed peripherally, while our data from brain slices and from mice which are predominatly cognitive in nature, strongly implicate the CNS.</p><p>Besides striatal and cortical cell death, growing evidence points to neuronal dysfunction as responsible for the earliest HD disturbances in cognitive and behavioral changes (<xref ref-type="bibr" rid="bib50">Lemiere et al., 2004</xref>; <xref ref-type="bibr" rid="bib73">Puigdellívol et al., 2016</xref>). Despite these early changes, no effective treatments are currently available to treat cognitive decline in HD. Moreover, the timing of intervention is also critical since atrophy and dysfunction progress with age and treatment may be different according to the stage of illness. In this scenario, and given the well-known role of both dopamine and histamine in synaptic plasticity and memory (<xref ref-type="bibr" rid="bib8">Cahill et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Ellender et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Haas et al., 2008</xref>; <xref ref-type="bibr" rid="bib44">Komater et al., 2005</xref>; <xref ref-type="bibr" rid="bib54">López de Maturana and Sánchez-Pernaute, 2010</xref>; <xref ref-type="bibr" rid="bib62">Mohsen et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Orsetti et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">Pascoli et al., 2009</xref>; <xref ref-type="bibr" rid="bib99">Wiescholleck and Manahan-Vaughan, 2014</xref>), it is possible that the therapeutic potential of H<sub>3</sub>R ligands as modulators of D<sub>1</sub>R-H<sub>3</sub>R heteromers could also be extended to improve learning impairments and cognitive decline in HD. This is supported by our data showing that chronic treatment with the H<sub>3</sub>R antagonist thioperamide at 5 months of age prevented motor learning deficits, as well as impaired spatial and recognition memories in mutant Hdh<sup>Q7/Q111</sup> mice. Importantly, thioperamide treatment does not induce off-target effects (such as alterations in spontaneous locomotor activity or anxiety-like behaviors) neither in wild-type Hdh<sup>Q7/Q7</sup> nor in mutant Hdh<sup>Q7/Q111</sup> mice. In addition, early chronic treatment with thioperamide prevented disruption of the heteromer at 6 and 8 months of age and the subsequent cognitive decline. It seems unlikely that there is a direct link between D<sub>1</sub>R-H<sub>3</sub>R heteromers and cognitive deficits, but the data do suggest that whatever neuronal changes occur during progression of the disease they are blocked or at minimum delayed. Importantly, we can say that D<sub>1</sub>R-H<sub>3</sub>R heteromers are required for this effect as thioperamide treatment at 7 months of age (when the heteromer is lost in HD mice) is not able to prevent cognitive and motor learning deficits. This latter result might explain the results of the effects that GSK189254, an H<sub>3</sub>R antagonist, have in a Q175 mouse model of HD (<xref ref-type="bibr" rid="bib98">Whittaker et al., 2017</xref>). The authors saw no change in motor performance and mild improvement in exploratory behavior as measured in the Open Field test and in cognitive function as measured by a T-maze. Our data suggest that D<sub>1</sub>R-H<sub>3</sub>R heteromer expression is crucial to the efficacy of H<sub>3</sub>R antagonists as a therapeutic option in HD.</p><p>What disease-driven neuronal changes are prevented by H<sub>3</sub>R antagonism through the D<sub>1</sub>R-H<sub>3</sub>R heteromer is not completely clear. However, we did find that chronic thioperamide treatment at early stages completely rescue the reduction in the density of spinophilin-immunoreactive puncta in HD mice in both hippocampal and cortical areas, suggesting that adequate dopaminergic signaling is required for normal forms of synaptic structural plasticity and cognitive processes. Substantial data support the importance of dopamine receptors for synaptic plasticity in the cortex and hippocampus (<xref ref-type="bibr" rid="bib51">Levy and Goldman-Rakic, 2000</xref>; <xref ref-type="bibr" rid="bib77">Robbins, 2000</xref>; <xref ref-type="bibr" rid="bib82">Sajikumar and Frey, 2004</xref>). In this view, any dopamine imbalance with both suboptimal and supra-optimal dopamine activity has been reported to modify cognitive performance (<xref ref-type="bibr" rid="bib58">Mattay et al., 2003</xref>; <xref ref-type="bibr" rid="bib92">Vijayraghavan et al., 2007</xref>). As the early stages of HD may reflect a hyperdopaminergic stage (<xref ref-type="bibr" rid="bib15">Chen et al., 2013a</xref>; <xref ref-type="bibr" rid="bib61">Mochel et al., 2011</xref>), treatments reducing dopamine signaling may have therapeutic benefits. In fact, dopamine-depleting drugs such as tetrabenazine or dopamine-stabilizers as pridopidine showed neuroprotective effects in HD mice (<xref ref-type="bibr" rid="bib96">Wang et al., 2010</xref>), and improve motor coordination abnormalities in HD patients (<xref ref-type="bibr" rid="bib40">Huntington Study Group, 2006</xref>; <xref ref-type="bibr" rid="bib18">de Yebenes et al., 2011</xref>), while specific D<sub>1</sub>R inhibition rescues electrophysiological changes in excitatory and inhibitory synaptic transmission in full-length HD mouse models (<xref ref-type="bibr" rid="bib2">André et al., 2011b</xref>). However, none of these treatments have demonstrated cognitive improvements. The suggestion that D<sub>1</sub>R-H<sub>3</sub>R heteromers may be legitimate targets for the treatment of HD shines a spotlight on what continues to be an elusive drug target. Indeed, in the context of this study, the loss of the heteromer in disease progression despite the fact that the receptors themselves are still expressed and functional, points to the heteromers as optimal targets rather than the single receptors. The concept of heteromers have been known for over a decade but physiologic examples have only recently come to be appreciated (<xref ref-type="bibr" rid="bib6">Bonaventura et al., 2015</xref>; <xref ref-type="bibr" rid="bib93">Viñals et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Baba et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Fribourg et al., 2011</xref>; <xref ref-type="bibr" rid="bib31">González et al., 2012a</xref> <xref ref-type="bibr" rid="bib32">González et al., 2012b</xref>; <xref ref-type="bibr" rid="bib43">Kern et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Navarro et al., 2015</xref>). In sum, our study showing that H<sub>3</sub>R antagonists can prevent learning and memory deficits by blocking D<sub>1</sub>R in D<sub>1</sub>R-H<sub>3</sub>R complexes, along with the role of these heteromers on neuronal cell death, predict a critical role of the histaminergic system as modulator of the dopamine imbalance in HD, and may help to overcome the deleterious effects of directly manipulating DA-production and/or signaling, thus opening new and important alternatives for HD therapeutics.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Cell line (<italic>H. sapiens</italic>)</td><td>HEK293 (Human embryonic kidney293 cells)</td><td>American Type Culture Collection</td><td/><td/></tr><tr><td>Cell line (<italic>M. musculus</italic>)</td><td>STHdh<sup>Q7</sup>; STHdh<sup>Q111</sup>(mouse striatal neuronal progenitor cells)</td><td>Dr M Macdonald (Center for Genomic Medicine, Boston, USA)</td><td/><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td>Hdh<sup>Q7/Q111</sup>; Hdh<sup>Q7/Q7</sup></td><td>Dr M Macdonald (Center for Genomic <break/>Medicine, Boston, USA)</td><td>Hdh<sup>Q111</sup> <break/>MGI:1861935</td><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td>R6/1; R6/2</td><td>The Jackson Laboratory (Bar Harbor, ME, USA)</td><td>R6/1: <break/>MGI:2389466 <break/>For R6/2: <break/>MGI:2386951</td><td/></tr><tr><td>Strain, strain background (<italic>H. sapiens</italic>)</td><td><italic>Post-mortem</italic> human brain sections containing caudate-putamen</td><td>Tissue Bank at Hospital Universitario Fundación Alcorcón (Madrid, Spain) <break/>Netherlands Brain Bank (Amsterdam, The Netherlands)</td><td/><td>For details and characteristics of human samples see: “Moreno E., et al., Neuropsychopharmacology. 2018 <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/28102227">28102227</ext-link>’</td></tr><tr><td>Antibody</td><td>anti-D<sub>1</sub>R (guinea pig)</td><td>Frontier Institute</td><td>Cat. # D-1R-GP-Af500 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2571595">AB_2571595</ext-link></td><td>Dilution: 1/200; 1/100</td></tr><tr><td>Antibody</td><td>anti-H<sub>3</sub>R (rabbit polyclonal)</td><td>Alpha diagnostic</td><td>Cat. # H3R31-A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1617140">AB_1617140</ext-link></td><td>Dilution: 1/200</td></tr><tr><td>Antibody</td><td>goat Alexa Fluor 488 anti-guinea pig antibody</td><td>Jackson Immunoresearch Laboratories</td><td>Cat. #106-545-003 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2337438">AB_2337438</ext-link></td><td>Dilution: 1/100</td></tr><tr><td>Antibody</td><td>anti-phospho-p38 MAPK (Thr180/Tyr182) (rabbit polyclonal)</td><td>Cell Signaling</td><td>Cat. #9211S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331641">AB_331641</ext-link></td><td>Dilution: 1/1,000</td></tr><tr><td>Antibody</td><td>anti-β-tubulin (mouse monoclonal)</td><td>Sigma</td><td>Cat# SAB4200715 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2827403">AB_2827403</ext-link></td><td>Dilution: 1/10,000</td></tr><tr><td>Antibody</td><td>IRDye 680 goat anti-rabbit antibody</td><td>Li-cor</td><td>Cat. #926–68071 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10956166">AB_10956166</ext-link></td><td>Dilution: 1/10,000</td></tr><tr><td>Antibody</td><td>IRDye 800 goat anti-mouse antibody</td><td>Li-cor</td><td>Cat. # 926–32210 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_621842">AB_621842</ext-link></td><td>Dilution: 1/10,000</td></tr><tr><td>Antibody</td><td>anti-spinophilin (rabbit polyclonal)</td><td>Millipore</td><td>Cat# 06–852 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_310266">AB_310266</ext-link></td><td>Dilution: 1/250</td></tr><tr><td>Antibody</td><td>Cy3 anti-rabbit secondary antibodies</td><td>Jackson ImmunoResearch <break/>Laboratories</td><td>Cat# 111-165-003 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2338000">AB_2338000</ext-link></td><td>Dilution: 1/200</td></tr><tr><td>Antibody</td><td>Anti-1C2 <break/>(mouse monoclonal)</td><td>Millipore</td><td>Cat# MAB1574 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_94263">AB_94263</ext-link></td><td>Dilution: 1/1,000</td></tr><tr><td>Recombinant DNA reagent</td><td>Clone V3LHS_638095</td><td>Thermo Scientific</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>Clone V3LHS_638091</td><td>Thermo Scientific</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>psPAX2</td><td>Addgene#12260</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMD2.G</td><td>Addgene#12259</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>RHS4346</td><td>Thermo Scientific</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>H<sub>3</sub>R-shRNA and control-shRNA</td><td>This study</td><td/><td>See Materials and methods</td></tr><tr><td>Sequence-based reagent</td><td>RT-qPCR primers</td><td>This study</td><td/><td>See Materials and methods</td></tr><tr><td>Peptide, recombinant protein</td><td>TAT-TM peptides</td><td>This study</td><td/><td>See Materials and methods</td></tr><tr><td>Commercial assay or kit</td><td>Duolink II in situ PLA detection reagent red Kit</td><td>Sigma</td><td>Cat. #DUO92008</td><td/></tr><tr><td>Commercial assay or kit</td><td>Duolink II PLA probe anti-guinea pig minus</td><td>Sigma</td><td>Cat. #DUO92010</td><td/></tr><tr><td>Commercial assay or kit</td><td>Duolink II PLA probe anti-rabbit plus</td><td>Sigma</td><td>Cat. #DUO92002 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2810940">AB_2810940</ext-link></td><td/></tr><tr><td>Commercial assay or kit</td><td>High Capacity cDNA Reverse Transcription Kit</td><td>Applied Biosystems</td><td>Cat. #4368814</td><td/></tr><tr><td>Commercial assay or kit</td><td>Amplified Luminiscent Proximity Homogeneous Assay kit</td><td>AlphaScreen <italic>SureFire</italic> p‐ERK 1/2 (Thr202/Tyr204) Assay Kits PerkinElmer</td><td>Cat. # TGRESB</td><td/></tr><tr><td>Commercial assay or kit</td><td>[<sup>3</sup>H] SCH 23390</td><td>PerkinElmer</td><td>Cat. # NET930</td><td>0.02 nM to 10 nM</td></tr><tr><td>Commercial assay or kit</td><td>[<sup>3</sup>H] R-α-methyl histamine</td><td>Perkinelmer</td><td>Cat. # NET1027</td><td>0.1 nM to 20 nM</td></tr><tr><td>Commercial assay or kit</td><td>SB 203580</td><td>Tocris</td><td>Cat. # 1402</td><td>1 μM; 10 μM <break/>(see Materials and methods)</td></tr><tr><td>Commercial assay or kit</td><td>SKF 81297</td><td>Tocris</td><td>Cat. # 1447</td><td>100 nM; 1 μM; 30 μM; 50 μM <break/>(see Materials and methods)</td></tr><tr><td>Commercial assay or kit</td><td>SCH 23390</td><td>Tocris</td><td>Cat. # 0925</td><td>one to 50 μM(see Materials and methods)</td></tr><tr><td>Commercial assay or kit</td><td>Thioperamide maleate salt</td><td>Sigma-Aldrich</td><td>Cat. #T123</td><td>10 μM (cells) <break/>10 mg/kg <break/>(mice)</td></tr><tr><td>Software, algorithm</td><td>Grafit</td><td>Erithacus <break/>(<ext-link ext-link-type="uri" xlink:href="http://www.erithacus.com/grafit/">http://www.erithacus.com/grafit/</ext-link>)</td><td/><td/></tr><tr><td>Software, algorithm</td><td>ImageJ</td><td>ImageJ (<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>)</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>SMART junior</td><td>Panlab <break/>(<ext-link ext-link-type="uri" xlink:href="http://www.panlab.com/panlabWeb/Software/php/displaySoft.php?nameSoft=SMART">http://www.panlab.com/panlabWeb/Software/php/displaySoft.php?nameSoft=SMART</ext-link> JUNIOR)</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_012154">SCR_012154</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism</td><td>GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>)</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015807">SCR_015807</ext-link></td><td>Version 6</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human brain slices</title><p>Paraffin-embedded <italic>post-mortem</italic> 4 μm-thick brain sections containing caudate-putamen were obtained and provided by the Tissue Bank at Hospital Universitario Fundación Alcorcón (Madrid, Spain) and the Netherlands Brain Bank (Amsterdam, The Netherlands) according to the standardized procedures of both institutions. The samples analyzed were from patients with HD (1 grade 0; 1 grade 1; 2 grade 2; 3 grade 3 and 3 grade four patients) and from age matched controls with no neurological disease (three subjects). All protocols were approved by the institutional ethic committees.</p></sec><sec id="s4-2"><title>Cell cultures</title><p>Mouse striatal wild-type STHdh<sup>Q7</sup> and mutant STHdh<sup>Q111</sup> cell lines were provided by Dr M. Macdonald (Center for Genomic Medicine, Boston, USA) and confirmed by PCR. These conditionally immortalized wild-type STHdh<sup>Q7</sup> and mutant STHdh<sup>Q111</sup> striatal neuronal progenitor cell lines expressing endogenous levels of normal and mutant huntingtin with 7 and 111 glutamines, respectively, have been described previously (<xref ref-type="bibr" rid="bib91">Trettel et al., 2000</xref>). These cells do not exhibit amino-terminal inclusions allowing the study of changes involved in early HD pathogenesis (<xref ref-type="bibr" rid="bib91">Trettel et al., 2000</xref>). Striatal cells were grown at 33°C in DMEM (Sigma-Aldrich), supplemented with 10% fetal bovine serum (FBS), 1% streptomycinpenicillin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 400 g/ml G418 (Geneticin; Invitrogen).</p><p>HEK293 cells were purchased from ATCC and kept below passage 20. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 100 μg/ml sodium pyruvate, 100 U/ml penicillin/streptomycin, essential medium non-essential amino acids solution (1/100) and 5% (v/v) heat inactivated fetal bovine serum (Invitrogen, Paisley, Scotland, UK) and were maintained at 37°C in an atmosphere with 5% CO2. Cells were transiently transfected with the corresponding fusion protein cDNA using Lipofectamine 3000 (Invitrogen, Paisley, Scotland, UK). Both cell lines were routinely test for mycoplasma contamination monthly by PCR.</p></sec><sec id="s4-3"><title>Animal models of HD</title><p>Knock-in mice, with targeted insertion of 109 CAG repeats that extends the glutamine segment in murine huntingtin to 111 residues, and the corresponding littermates having seven glutamine residues were maintained on a C57BL/6 genetic background (<xref ref-type="bibr" rid="bib52">Lloret et al., 2006</xref>). Hdh<sup>Q7/Q111</sup> heterozygous males and females were intercrossed to generate age-matched Hdh<sup>Q7/Q111</sup> heterozygous and Hdh<sup>Q7/Q7</sup> wild-type littermates. Only males were used for all experiments. Hemizigous male mice transgenic for exon 1 of the human huntingtin gene with a greatly expanded CAG repeat (~115 CAG repeats in R6/1 mice and ~160 CAG repeats in R6/2 mice) (<xref ref-type="bibr" rid="bib57">Mangiarini et al., 1996</xref>) and wild-type littermates were used when indicated in proximity ligation assays. Animals were housed under a 12 hr light/dark cycle with food and water ad libitum.</p></sec><sec id="s4-4"><title>Mouse brain slices preparation</title><p>For PLA experiments, 2-, 4-, 6- and 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice were deeply anesthetized and immediately perfused transcardially with saline (PBS) followed by 4% paraformaldehyde (PFA)/phosphate buffer. Brains were removed and post-fixed overnight in the same solution, cryoprotected by immersion in 10, 20, 30% gradient sucrose (24 hr for each sucrose gradient) at 4°C and then frozen in dry ice-cooled methylbutane. Serial coronal cryostat sections (30 µm) through the whole brain were collected in PBS-0.025% azide as free-floating sections and stored at 4°C until PLA experiments were performed. For cell death determination, Hdh<sup>Q7/Q111</sup> and Hdh<sup>Q7/Q7</sup> mice were killed by cervical dislocation at the age of 4, 5 and 8 months. Mouse brains were rapidly removed and placed in ice-cold oxygenated (O<sub>2</sub>/CO<sub>2</sub>: 95%/5%) Krebs-HCO<sub>3</sub><bold><sup>-</sup></bold> buffer (124 mM NaCl, 4 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 1.5 mM MgSO<sub>4</sub>, 1.5 mM CaCl<sub>2</sub>, 10 mM glucose and 26 mM NaHCO<sub>3</sub>, pH 7.4). Cerebral hemisferes were split and sliced coronally using a McIlwain chopper (Ted Pella, Inc, California) in sterile conditions. Striatum, cortex and hippocampal slices (300 µm thick) were kept at 4°C in Krebs-HCO<sub>3</sub><bold><sup>-</sup></bold> buffer during the dissection and transferred into a Millicell Insert (Millipore).</p></sec><sec id="s4-5"><title>Cell death determination in striatal cells and in mouse organotypic slice cultures</title><p>Striatal STHdh<sup>Q7</sup> or STHdh<sup>Q111</sup> cells were grown to reach 50% of confluence on 12-well plates containing 3 cm<sup>2</sup>-glass coverslips. Medium was then replaced by a new supplemented medium containing 0.5% FBS. Vehicle, SCH 23390, thioperamide or SB 203580 were added at the indicated concentrations to cells and incubated for 1 hr before the addition of D<sub>1</sub>R. When TAT-TM peptides were applied to cell cultures, these were added 4 hr before the addition of D<sub>1</sub>R agonist. After agonist addition, an additional incubation period of 24 hr was performed. Then cells were washed twice in cold-PBS and fixed with 4% paraformaldehyde for 1 hr at 4°C. Sample nuclei were stained with Hoechst 1:1000. Stained cells were then washed with PBS and mounted under glass coverslips with Mowiol. A minimum of 10 fields were taken from each coverslip using a fluorescence microscope and the plugin Image-based Tool for Counting Nuclei for ImageJ was used for the quantification of the total nuclei. In mouse organotypic cultures, brain slices (300 μm thickness, see above) were cultured for 24 hr into a Millicell Insert in Neurobasal medium supplemented with 20% horse serum, 0.5% B27, 2 mM L-glutamine, 100 µg/ml sodium pyruvate, non-essential amino acids solution (1/100) and 100 units/ml penicillin/streptomycin (all supplements were from Invitrogen, Paisley, Scotland, UK) before replacing with fresh medium. Vehicle, SCH 23390, thioperamide were added at the indicated concentrations to organotypic cultures and incubated for 1 hr before the addition of D<sub>1</sub>R agonist. TAT-TM peptides were applied to cell cultures 4 hr before the addition of D<sub>1</sub>R agonist. After agonist addition, an additional incubation period of 48 hr was performed. Then, 10 μM propidium iodide (PI) was added to organotypic cultures and maintained at 37°C for 1 hr. Organotypic cultures were washed twice in cold-PBS and fixed with 4% paraformaldehyde for 1 hr at 4°C. Total nuclei were stained with Hoechst 1:1000. The Hoechst stained and PI positive nuclei in organotypic cultures were counted to evaluate cell death in the brain slices. Quantification was performed using Leica SP2 confocal microscope (20x; UV, 561 lasers) and the quantification performed with the program Image-based Tool for Counting Nuclei for ImageJ. Cell death is expressed as the percentage of PI positive cells in the total Hoechst-stained nuclei.</p></sec><sec id="s4-6"><title>Lentivirus production and cell transduction</title><p>Silencing lentiviral vectors were produced by co-transfecting HEK293 producing cellsT with lentiviral silencing plasmids GIPZ Human histamine H3 receptor shRNA (Clone V3LHS_638095 or Clone V3LHS_638091, Thermo Scientific) with packing plasmid psPAX2 and envelope coding plasmid pMD2.G (Addgene#12260 and #12259, respectively) using the calcium phosphate method. For production of control non silencing lentiviral particles the H<sub>3</sub>R silencing plasmid were substituted with GIPZ Non-silencing Lentiviral shRNA Control (RHS4346, Thermoscientific). Infectious lentiviral particles were harvested at 48 hr post-transfection, centrifuged 10 min at 900 g to get rid of cell debris, and then filtered through 0.45 μm cellulose acetate filters. The titer of recombinant lentivirus was determined by serial dilution on HEK293T cells. For lentivirus transduction, striatal cells were subcultured to 50% confluence, cells were transduced with H<sub>3</sub>R-shRNA-expressing lentivirus obtained with plasmid (Clone V3LHS_638095) or control-shRNA-expressing lentivirus (LV control) at a multiplicity of infection (MOI) of 10 in the presence of polybrene 5 µg/ml. Virus-containing supernatant was removed after 3 hr. Puromycin was added to the culturing media at the final concentration of 1 µg/ml 2 days after infection. 5 days after puromycin selection cells were transduced with the second H<sub>3</sub>R-shRNA-expressing lentivirus obtained with plasmid Clone V3LHS_638091 to improve the level of silencing achieved. LV control infected cells were re-infected with control-shRNA-expressing lentivirus. The second infection was carried out as the first one. Cells were tested 72 hr after the second transduction was performed.</p></sec><sec id="s4-7"><title>RNA and real-time PCR</title><p>RNA was extracted using TRIzol Reagent (Molecular Research Center). 10 μg of total RNA were treated with RQ1 RNAse free DNAse (Promega) according to manufacturer instruction. DNAse treated DNA was quantified again and cDNA was synthesized using 2 μg total RNA with a High Capacity cDNA Reverse Transcription Kit; (Applied Biosystems). The mRNAs of actin, H3R and D1R were amplified by real-time (RT)-PCR using 1 μL cDNA and power SYBER green PCR Master Mix (Applied Biosystems) on a 7500 Real Time PCR system (Applied Biosystems). Primer sequences are as follows: MsACT For: <named-content content-type="sequence">ATGAGCTGCCTGACGGCCAGGTCAT</named-content>, MsACT Rev: <named-content content-type="sequence">TGGTACCACCAGACAGCAC</named-content> TGTGTT, H<sub>3</sub>R For: <named-content content-type="sequence">GCAACGCGCTGGTCATGCTC</named-content>, H<sub>3</sub>R Rev: <named-content content-type="sequence">CCCCGGCCAAAGGTCCAACG</named-content>, D<sub>1</sub>R FOR: <named-content content-type="sequence">ACCTCTGTGTGATCAGCGTG</named-content>, AND D<sub>1</sub>R REV: <named-content content-type="sequence">GCGTATGTCCTGCTCAACCT</named-content>. Thermal cycling conditions for amplification were set at 50°C for 2 min and 95°C for 10 min, respectively. PCR denaturing was set at 95°C for 15 s and annealing/extending at 60°C for 60 s for 40 cycles. mRNA levels normalized for actin are expressed as fold change relative to control cells. The results were quantified with the comparative <italic>C</italic><sub>t</sub> method (known as the 2<sup>−δδCt</sup> method).</p></sec><sec id="s4-8"><title>In Situ Proximity Ligation Assays (PLA)</title><p>Cells or mouse or human brain slices were mounted on glass slides and treated or not with the indicated concentrations of receptor ligands or TAT-TM peptides for the indicated time. Then, cells or slices were thawed at 4°C, washed in 50 mM Tris-HCl, 0.9% NaCl pH 7.8 buffer (TBS), permeabilized with TBS containing 0.01% Triton X-100 for 10 min and successively washed with TBS. Heteromers were detected using the Duolink II in situ PLA detection Kit (OLink; Bioscience, Uppsala, Sweden) following the instructions of the supplier. A mixture of equal amounts of the primary antibodies: guinea pig anti-D<sub>1</sub>R antibody (1/200 Frontier Institute, Ishikari, Hokkaido, Japan) and rabbit anti-H<sub>3</sub>R antibody (1:200, Alpha diagnostic, San Antonio, Texas, USA) were used to detect D<sub>1</sub>R-H<sub>3</sub>R heteromers together with PLA probes detecting guinea pig or rabbit antibodies, Duolink II PLA probe anti-guinea pig minus and Duolink II PLA probe anti-rabbit plus. Then samples were processed for ligation and amplification with a Detection Reagent Red and were mounted using a DAPI-containing mounting medium. Samples were observed in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with an apochromatic 63X oil-immersion objective (N.A. 1.4), and a 405 nm and a 561 nm laser lines. For each field of view a stack of two channels (one per staining) and 9 to 15 Z stacks with a step size of 1 μm were acquired. For PLA with brain slices, after image processing, the red channel was depicted in green color to facilitate detection on the blue stained nucleus and maintaining the color intensity constant for all images. A quantification of cells containing one or more spots versus total cells (blue nucleus) and, in cells containing spots, the ratio r (number of red spots/cell containing spots) were determined, using the Fiji package (http://pacific. mpi-cbg.de/), considering a total of 600–800 cells from 4 to 10 different fields within each brain region from three different mice per group or from three human control subjects, 3 human grade 3 or grade 4 HD patients, 2 grade 0 or grade 1 HD patients or 1 grade 2 HD patient. Nuclei and spots were counted on the maximum projections of each image stack. After getting the projection, each channel was processed individually. The nuclei were segmented by filtering with a median filter, subtracting the background, enhancing the contrast with the Contrast Limited Adaptive Histogram Equalization (CLAHE) plug-in and finally applying a threshold to obtain the binary image and the regions of interest (ROI) around each nucleus. Red spots images were also filtered and thresholded to obtain the binary images. Red spots were counted in each of the ROIs obtained in the nuclei images.</p></sec><sec id="s4-9"><title>Membrane preparation and radioligand binding</title><p>Striatal cells or mouse striatal, cortical or hippocampal tissue were homogenized in 50 mM Tris-HCl buffer, pH 7.4, containing a protease inhibitor mixture (1/1000, Sigma). The cellular debris was removed by centrifugation at 13,000 g for 5 min at 4°C, and membranes were obtained by centrifugation at 105,000 g for 1 hr at 4°C. Membranes were washed three more times at the same conditions before use. Ligand binding was performed with membrane suspension (0.2 mg of protein/ml) in 50 mM Tris–HCl buffer, pH 7.4 containing 10 mM MgCl<sub>2</sub>, at 25°C. To obtain saturation curves, membranes were incubated with increasing free concentrations of [<sup>3</sup>H] SCH 23390 (0.02 nM to 10 nM, PerkinElmer, Boston, MO, USA) or [<sup>3</sup>H] R-α-methyl histamine (0.1 nM to 20 nM, PerkinElmer, Boston, MO, USA) providing enough time to achieve stable equilibrium for the lower ligand concentrations. Nonspecific binding was determined in the presence of 30 µM non-labeled ligand. Free and membrane bound ligand were separated by rapid filtration of 500 µl aliquots in a cell harvester (Brandel, Gaithersburg, MD, USA) through Whatman GF/C filters embedded in 0.3% polyethylenimine that were subsequently washed for 5 s with 5 ml of ice-cold Tris–HCl buffer. The filters were incubated overnight with 10 ml of Ecoscint H scintillation cocktail (National Diagnostics, Atlanta, GA, USA) at room temperature and radioactivity counts were determined using a Tri-Carb 1600 scintillation counter (PerkinElmer, Boston, MO, USA) with an efficiency of 62%. Protein was quantified by the bicinchoninic acid method (Pierce Chemical Co., Rockford, IL, USA) using bovine serum albumin dilutions as standard. Monophasic saturation curves were analyzed by non-linear regression, using the commercial Grafit software (Erithacus Software), by fitting the binding data to the equation previously deduced (equation (3) in <xref ref-type="bibr" rid="bib33">Gracia et al., 2013</xref>.</p></sec><sec id="s4-10"><title>Immunocytochemistry</title><p>Cells (60% confluence) were treated with vehicle or 30 µM SKF 81297 and after 45 min cells were kept at 4°C to block endocytosis/exocytosis, washed twice in cold-PBS, fixed in 4% paraformaldehyde for 15 min and washed with PBS containing 20 mM glycine (buffer A) to quench the aldehyde groups. After permeabilization with buffer A containing 0.05% Triton X-100 for 5 min, cells were washed with buffer A containing 1% bovine serum albumin (blocking solution) for 1 hr and labeled with the primary guinea pig anti-D<sub>1</sub>R antibody (1/100, Frontier Institute, Ishikari, Hokkaido, Japan, ON at 4°C), washed with blocking solution, and stained with the secondary goat Alexa Fluor 488 anti-guinea pig antibody (1:100, Jackson Immunoresearch Laboratories, West Grove, PA, USA, 2 hr at RT). Samples were washed twice with blocking solution, once with buffer A and finally with PBS. Nuclei were stained with 1:1000 Hoechst. Cells were mounted with Mowiol and observed in a Leica SP2 confocal microscope.</p></sec><sec id="s4-11"><title>Signaling in striatal cells</title><p>To determine ERK1/2 phosphorylation, cells (35,000/well) were cultured with a non-supplemented medium overnight before pre-treated at 25°C for 20 min with the antagonists and stimulated for an additional 7 min with the indicated agonists. Phosphorylation was determined by alpha-screen bead-based technology using the Amplified Luminescence Proximity Homogeneous Assay kit (PerkinElmer, Waltham, MA, USA) and the Enspire Multimode Plate Reader (PerkinElmer) following the instructions of the supplier. To determine calcium release, striatal cells were transfected with 4 μg of GCaMP6 calcium sensor (<xref ref-type="bibr" rid="bib16">Chen et al., 2013b</xref>) using lipofectamine 3000. After 48 hr, cells were incubated (0.2 mg of protein/ml in 96-well black, clear bottom microtiter plates) with Mg<sup>+2</sup>-free Locke’s buffer pH 7.4 (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO<sub>3</sub>, 2.3 mM CaCl<sub>2</sub>, 5.6 mM glucose and 5 mM HEPES) supplemented with 10 μM glycine. When TAT-TM peptides treatment was performed they were added 1 hr before the addition of receptor ligands at the indicated concentration. Fluorescence emission intensity of GCaMP6s was recorded at 515 nm upon excitation at 488 nm on an EnSpire Multimode Plate Reader (PerkinElmer, Boston, MO, USA) for 330 s every 5 s and 100 flashes per well. The fluorescence gain was defined as a delta function of ΔF/F(t) = (F(t) – F0)/F0, where F0 is the average fluorescence intensity in the first six measures from the start of recording and F(t) is the fluorescence intensity at a given time and was expressed in %. To determine p38 phosphorylation, striatal cells (80% confluence) were cultured with a non-supplemented medium 4 hr before the addition of the indicated ligand concentration for the indicated time and were lysed with 50 mM Tris-HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM β-glycerophosphate, 1% Triton X-100, 20 µM phenyl-arsine oxide, 0.4 mM NaVO<sub>4</sub> and protease inhibitor cocktail. Lysates (20 µg protein) were processed for western blot a mixture of a rabbit anti-phospho-p38 MAPK (Thr180/Tyr182) antibody (1:1000, Cell Signaling) and a mouse anti-β-tubulin antibody (1:10,000, Sigma). Bands were visualized by the addition of a mixture of IRDye 680 anti-rabbit antibody (1:10,000, LI-COR Biosciences) and IRDye 800 anti-mouse antibody (1:10,000, LI-COR Biosciences) for 2 hr at room temperature and scanned by the Odyssey infrared scanner (LI-COR Biosciences). Band densities were quantified using the Odyssey scanner software. The level of phosphorylated p38 MAPK was normalized for differences in loading using the β-tubulin band intensities.</p></sec><sec id="s4-12"><title>Mice thioperamide treatment</title><p>Thioperamide maleate salt (Sigma-Aldrich, St. Louis, USA) was prepared fresh daily being dissolved in sterile 0,9% saline (NaCl) in order to deliver a final dose of 10 mg/kg in a final volume of 0.01 ml/g of body weight, as previously described (<xref ref-type="bibr" rid="bib13">Charlier et al., 2013</xref>). The vehicle treatment consisted of an equal volume of saline solution. All injections were given via the intra-peritoneal route (<italic>i.p</italic>). Three <italic>i.p</italic> injections per week were administered to wild-type Hdh<sup>Q7/Q7</sup> and mutant knock-in Hdh<sup>Q7/Q111</sup> mice from 5 months of age until 6 months of age (when one cohort of animals was perfused to analyze PLA after behavioral assessment) or until 8 months of age (when a second cohort of animals were perfused to analyze PLA at this more advanced disease stage). A total of 11 saline-Hdh<sup>Q7/Q7</sup> mice, 10 thioperamide-Hdh<sup>Q7/Q7</sup> mice, seven saline-Hdh<sup>Q7/Q111</sup> mice and nine thioperamide-Hdh<sup>Q7/Q111</sup> mice were treated. For these experiments, a total of 11 saline-Hdh<sup>Q7/Q7</sup> mice, 10 thioperamide-Hdh<sup>Q7/Q7</sup> mice, seven saline-Hdh<sup>Q7/Q111</sup> mice and nine thioperamide-Hdh<sup>Q7/Q111</sup> mice were treated. Similarly, three <italic>i.p</italic> injections per week were administered to wild-type Hdh<sup>Q7/Q7</sup> and mutant knock-in Hdh<sup>Q7/Q111</sup> mice from 7 months of age until 8 months of age to perform the behavioral studies when the D<sub>1</sub>R-H<sub>3</sub>R heteromers were lost. For these experiments, a total of 11 saline-Hdh<sup>Q7/Q7</sup> mice, 12 thioperamide-Hdh<sup>Q7/Q7</sup> mice, 10 saline-Hdh<sup>Q7/Q111</sup> mice and 11 thioperamide-Hdh<sup>Q7/Q111</sup> mice were treated. All treatments were performed in the afternoon to avoid the stress caused by the treatments during the behavioral assessment. Thus, during behavioral analysis treatments were performed after the evaluation of motor learning or cognitive tasks.</p></sec><sec id="s4-13"><title>Behavior assays</title><p>Accelerating rotarod was performed as previously described (<xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>). Animals were placed on a motorized rod (30 mm diameter). The rotation speed gradually increased from 4 to 40 rpm over the course of 5 min. The time latency was recorded when the animal was unable to keep up on the rotarod with the increasing speed and fell. Rotarod training/testing was performed as four trials per day during three consecutive days. A resting period of one hour was left between trials. The rotarod apparatus was rigorously cleaned with ethanol between animal trials in order to avoid odors.</p><p>For T-maze spontaneous alternation task (T-SAT), the T-maze apparatus used was a wooden maze consisting of three arms, two of them situated at 180° from each other, and the third, representing the stem arm of the T, situated at 90° with respect to the other two. All arms were 45 cm long, 8 cm wide and enclosed by a 20 cm wall. Two identical guillotine doors were placed in the entry of the arms situated at 180°. In the training trial, one arm was closed (new arm) and mice were placed in the stem arm of the T (home arm) and allowed to explore this arm and the other available arm (old arm) for 10 min, after which they were returned to the home cage. After 5 hr (LTM), mice were placed in the stem arm of the T-maze and allowed to freely explore all three arms for 5 min. The arm preference was determined by calculating the time spent in each arm x 100/time spent in both arms (old and new arm). The T-maze was rigorously cleaned with ethanol between animal trials in order to avoid odors.</p><p>Novel object recognition test (NORT) consisted in a white circular arena with 40 cm diameter and 40 cm high. Mice were first habituated to the open field arena in the absence of objects (2 days, 15 min/day). During these two days of habitation, several parameters were measured to ensure the proper habituation of all mice in the new ambient. As a measure of anxiety or motivation behaviors, the distance that each mice rove in the periphery or in the center of the open field arena was measured as the rove distance in the periphery or in the center x 100/the total distance. The same analysis was performed by counting the number of entries in the periphery and in the center as well as the time that each mouse spent exploring the periphery or the center. The total distance that each mice rove during these two days of habituation was also recorded as a measure to evaluate spontaneous locomotor activity. On the third day, two similar objects were presented to each mouse during 10 min (A, A’ condition) after which the mice were returned to their home cage. Twenty-four hours later (LTM), the same animals were re-tested for 5 min in the arena with a familiar and a new object (A, B condition). The object preference was measured as the time exploring each object ×100/time exploring both objects. The arena was rigorously cleaned with ethanol between animal trials in order to avoid odors. Animals were tracked and recorded with SMART junior software (Panlab, Spain).</p></sec><sec id="s4-14"><title>Immunohistochemistry, confocal microscopy and immunofluorescence-positive puncta counting</title><p>Saline and thioperamide-treated heterozygous mutant Hdh<sup>Q7/Q111</sup> and WT Hdh<sup>Q7/Q7</sup> mice at 6 months of age (n = 3 per group) were deeply anesthetized and immediately perfused transcardially with saline followed by 4% paraformaldehyde (PFA)/phosphate buffer. Brains were removed and postfixed overnight in the same solution, cryoprotected by immersion in 30% sucrose and then frozen in dry ice-cooled methylbutane. Serial coronal cryostat sections (30 μm) through the whole brain were collected in PBS as free-floating sections. Sections were rinsed three times in PBS and permeabilized and blocked in PBS containing 0.3% Triton X-100% and 3% normal goat serum (Pierce Biotechnology, Rockford, IL) for 15 min at room temperature. The sections were then washed in PBS and incubated overnight at 4°C with Spinophilin (1:250, Millipore) antibody that were detected with Cy3 anti-rabbit secondary antibodies (1:200, Jackson ImmunoResearch, West Grove, PA). As negative controls, some sections were processed as described in the absence of primary antibody and no signal was detected. Confocal microscopy analysis and immunofluorescence-positive puncta counting spinophilin-positive spine-like structures was examined as previously described (<xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>). Briefly, the images were acquired with Zeiss LSM510 META confocal microscope with HeNe lasers. Images were taken using a × 63 numerical aperture objective with ×4 digital zoom and standard (one Airy disc) pinhole. Three coronal sections (30 μm thick) per animal (n = 3 per group) spaced 0.24 mm apart containing the motor area M1 or CA1 hippocampus were used. For each slice, we obtained three fields/cortical layer (I, II/III and V) of the M1 area and three fields/CA1 hippocampus (<italic>stratum oriens</italic> and <italic>stratum radiatum</italic>). The number and area of spinophilin-positive puncta were measured using NIH ImageJ version 1.33 by Wayne Rasband (National Institutes of Health, Bethesda, MD). To analyze spinophilin immunolabeling, brightness and contrast of fluorescence images were adjusted so that only punctate fluorescence, but no weak diffuse background labeling was visible. In the article, we use the term ‘puncta’ and ‘cluster’ interchangeable to refer to discrete points of protein at the fluorescence microscope. Positive puncta/cluster within a specific field was recognized by identifying the presence of overlapping 10–100 pixels.</p></sec><sec id="s4-15"><title>Western blot analysis</title><p>Saline and thioperamide-treated heterozygous mutant Hdh<sup>Q7/Q111</sup> and WT Hdh<sup>Q7/Q7</sup>, mice were killed by cervical dislocation at 6 months of age, after behavioral assessment. Brains were quickly removed, dissected, frozen in dry ice and stored at −80°C until use. Protein extraction (n = 5–9 per group, only males) and western blot analysis were performed as previously described (<xref ref-type="bibr" rid="bib72">Puigdellívol et al., 2015</xref>). The primary antibody 1C2 (1:1,000, Millipore) was used. Loading control was performed by reproving the membranes with an antibody to α-actin (1:20,000, MP Biochemicals). ImageJ software was used to quantify the different immunoreactive bands relative to the intensity of the α- actin band in the same membranes within a linear range of detection for the enhanced chemiluminescent kit reagent. Data are expressed as the mean ± SEM of band density.</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>All the results were analyzed using GraphPad Prism software version 6.0. Data were presented as mean ± standard error of the means (SEM). Statistical analysis was performed using the unpaired two-sided Student's <italic>t</italic> test (95% confidence), one-way ANOVA or two-way ANOVA with the Bonferroni's <italic>post hoc</italic> test. Values of p&lt;0.05 were considered statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are very grateful to Ana Lopez (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017–0729, Ministry of Science, Innovation and Universities) for mouse colony assistance. Dr. Teresa Rodrigo and the staff of the animal care facility (Facultat de Psicologia, Universitat de Barcelona), for their support and advice. We thank Manel Bosch at UB and Paul Thomas at the Henry Welcome Laboratory for Cell Imaging at UEA for their help with the microscopy. This work was supported by grants from Ministerio de Economia y Competitividad (RTI2018-094374-B-I00 to SG, SAF2017-88076-R to JA, RTI2018-095311-B-I00 to MG, and SAF-2017–87629 R to EC) Centro de Investigacion Biomédicas en Red sobre Enfermedades Neurodegenerativas (CIBERNED); RETICS (Red de Terapia Celular; RD16/0011/0012); Grant 20140610 from Fundació La Marató de TV3 to EC; RSC Grant Project RG140118; Jerome LeJeune Foundation FJL-01/01/2013; BBSRC BB/N504282/3 and start-up funds from QMUL.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Performed and analyzed viability, calcium, internalization and organotypic culture experiments, Designed the experiments, analysed the results and wrote the manuscript</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Data curation, Performed all the treatments in mice, Conducted and analyzed the behavioral tests, Obtained all the tissue samples and prepared tissue slices for PLA, organotypic culture and mRNA experiments, Performed and analyzed western blot experiments and conducted and analysed spinophilin-immureactive experiments, Designed the experiments, analysed the results and wrote the manuscript.</p></fn><fn fn-type="con" id="con3"><p>Investigation, Performed PLA experiments and PLA quantification</p></fn><fn fn-type="con" id="con4"><p>Investigation, Assisted with function and viability experiments in cells and organotypic culture</p></fn><fn fn-type="con" id="con5"><p>Investigation, Performed the binding experiments and assisted with calcium and cell death experiments</p></fn><fn fn-type="con" id="con6"><p>Investigation, Performed all the shRNA related experiments and conducted and analyzed mRNA experiments</p></fn><fn fn-type="con" id="con7"><p>Investigation, Helped with the R6 and human PLA experiments</p></fn><fn fn-type="con" id="con8"><p>Resources, Designed, synthesized and purified the disrupting peptides</p></fn><fn fn-type="con" id="con9"><p>Resources, Aided with the cell experiments</p></fn><fn fn-type="con" id="con10"><p>Investigation, Performed and analyzed binding experiments</p></fn><fn fn-type="con" id="con11"><p>Investigation, Performed and analyzed binding experiments</p></fn><fn fn-type="con" id="con12"><p>Resources, Aided with the disrupting peptide experiments</p></fn><fn fn-type="con" id="con13"><p>Resources, Funding acquisition, Provided R6 mice samples and all the human samples, Discussed the results and edited the manuscript</p></fn><fn fn-type="con" id="con14"><p>Supervision, Designed, supervised experiments, discussed, and helped write the manuscript</p></fn><fn fn-type="con" id="con15"><p>Funding acquisition, Aided with the in vivo experiments</p></fn><fn fn-type="con" id="con16"><p>Resources, Funding acquisition, Aided with the disrupting peptide experiments</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Project administration, Conceived the idea, designed, supervised and coordinated the project, analyzed the results, and wrote the manuscript</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Project administration, Conceived the idea, designed, supervised and coordinated the project, analyzed the results, and wrote the manuscript</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures involving animals were performed in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and approved by the local animal care committee of the Universitat de Barcelona (99/01) and Generalitat de Catalunya (99/1094), in accordance with the European (2010/63/EU) and Spanish (RD53/2013) regulations for the care and use of laboratory animals. All protocols involving postmortem human sample were approved by the institutional ethic committees.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>H<sub>3</sub>R and D<sub>1</sub>R binding parameters in STHdh<sup>Q7</sup>, STHdh<sup>Q111</sup> cells.</title><p>Striatal cells were homogenized in 50 mM Tris-HCl buffer and ligand binding was performed with membrane suspension (see materials and methods). Binding parameters from saturation and competition curves were obtained using Grafit software by fitting the binding data to the equation previously deduced (equation (3) in <xref ref-type="bibr" rid="bib33">Gracia et al., 2013</xref>. Data are mean ± SEM of experiments performed per triplicate.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-51093-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>H<sub>3</sub>R and D<sub>1</sub>R binding parameters in different brain regions from 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice.</title><p>Mouse striatal, cortical or hippocampal tissue were homogenized in 50 mM Tris-HCl buffer and ligand binding was performed with membrane suspension (see online methods). Binding parameters from saturation and competition curves were obtained using Grafit software by fitting the binding data to the equation previously deduced (equation (3) in <xref ref-type="bibr" rid="bib33">Gracia et al., 2013</xref>. Data are mean ± SEM of experiments performed per triplicate (n = 6 Hdh<sup>Q7/Q7</sup> and n = 5 Hdh<sup>Q7/Q111</sup>).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-51093-supp2-v2.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>H<sub>3</sub>R and D<sub>1</sub>R mRNA expression levels the striatum of 4- and 8-month-old Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> mice.</title><p>RT-PCR was performed in striatal extracts from Hdh<sup>Q7/Q7</sup> and Hdh<sup>Q7/Q111</sup> at 4 and 8 months of age as described in materials and methods. Results were normalized to actin gene expression. Data represent mean ± SEM (n = 3–4) of experiments performed in duplicate and are expressed as fold change of wild-type animals. Student’s two-tailed <italic>t</italic> test was performed.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-51093-supp3-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-51093-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>André</surname> <given-names>VM</given-names></name><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Fisher</surname> <given-names>YE</given-names></name><name><surname>Huynh</surname> <given-names>M</given-names></name><name><surname>Bardakjian</surname> <given-names>N</given-names></name><name><surname>Singh</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>XW</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>Differential electrophysiological changes in striatal output neurons in Huntington's disease</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>1170</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3539-10.2011</pub-id><pub-id pub-id-type="pmid">21273402</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>André</surname> <given-names>VM</given-names></name><name><surname>Fisher</surname> <given-names>YE</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's Disease</article-title><source>Frontiers in Systems Neuroscience</source><volume>5</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.3389/fnsys.2011.00046</pub-id><pub-id pub-id-type="pmid">21720523</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrasate</surname> <given-names>M</given-names></name><name><surname>Finkbeiner</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Protein aggregates in Huntington's disease</article-title><source>Experimental Neurology</source><volume>238</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2011.12.013</pub-id><pub-id pub-id-type="pmid">22200539</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname> <given-names>K</given-names></name><name><surname>Benleulmi-Chaachoua</surname> <given-names>A</given-names></name><name><surname>Journé</surname> <given-names>AS</given-names></name><name><surname>Kamal</surname> <given-names>M</given-names></name><name><surname>Guillaume</surname> <given-names>JL</given-names></name><name><surname>Dussaud</surname> <given-names>S</given-names></name><name><surname>Gbahou</surname> <given-names>F</given-names></name><name><surname>Yettou</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Contreras-Alcantara</surname> <given-names>S</given-names></name><name><surname>Jockers</surname> <given-names>R</given-names></name><name><surname>Tosini</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>ra89</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004302</pub-id><pub-id pub-id-type="pmid">24106342</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname> <given-names>JM</given-names></name><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The physiology, signaling, and pharmacology of dopamine receptors</article-title><source>Pharmacological Reviews</source><volume>63</volume><fpage>182</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1124/pr.110.002642</pub-id><pub-id pub-id-type="pmid">21303898</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonaventura</surname> <given-names>J</given-names></name><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Casadó-Anguera</surname> <given-names>V</given-names></name><name><surname>Azdad</surname> <given-names>K</given-names></name><name><surname>Rea</surname> <given-names>W</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Brugarolas</surname> <given-names>M</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Volkow</surname> <given-names>ND</given-names></name><name><surname>Schiffmann</surname> <given-names>SN</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Allosteric interactions between agonists and antagonists within the Adenosine A2A receptor-dopamine D2 receptor heterotetramer</article-title><source>PNAS</source><volume>112</volume><fpage>E3609</fpage><lpage>E3618</lpage><pub-id pub-id-type="doi">10.1073/pnas.1507704112</pub-id><pub-id pub-id-type="pmid">26100888</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname> <given-names>V</given-names></name><name><surname>Giralt</surname> <given-names>A</given-names></name><name><surname>Enriquez-Barreto</surname> <given-names>L</given-names></name><name><surname>Puigdellívol</surname> <given-names>M</given-names></name><name><surname>Suelves</surname> <given-names>N</given-names></name><name><surname>Zamora-Moratalla</surname> <given-names>A</given-names></name><name><surname>Ballesteros</surname> <given-names>JJ</given-names></name><name><surname>Martín</surname> <given-names>ED</given-names></name><name><surname>Dominguez-Iturza</surname> <given-names>N</given-names></name><name><surname>Morales</surname> <given-names>M</given-names></name><name><surname>Alberch</surname> <given-names>J</given-names></name><name><surname>Ginés</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>4411</fpage><lpage>4428</lpage><pub-id pub-id-type="doi">10.1172/JCI74809</pub-id><pub-id pub-id-type="pmid">25180603</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname> <given-names>E</given-names></name><name><surname>Pascoli</surname> <given-names>V</given-names></name><name><surname>Trifilieff</surname> <given-names>P</given-names></name><name><surname>Savoldi</surname> <given-names>D</given-names></name><name><surname>Kappès</surname> <given-names>V</given-names></name><name><surname>Lüscher</surname> <given-names>C</given-names></name><name><surname>Caboche</surname> <given-names>J</given-names></name><name><surname>Vanhoutte</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>D1R/GluN1 complexes in the striatum integrate dopamine and glutamate signalling to control synaptic plasticity and cocaine-induced responses</article-title><source>Molecular Psychiatry</source><volume>19</volume><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1038/mp.2014.73</pub-id><pub-id pub-id-type="pmid">25070539</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calebiro</surname> <given-names>D</given-names></name><name><surname>Nikolaev</surname> <given-names>VO</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>Imaging of persistent cAMP signaling by internalized G protein-coupled receptors</article-title><source>Journal of Molecular Endocrinology</source><volume>45</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1677/JME-10-0014</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calebiro</surname> <given-names>D</given-names></name><name><surname>Nikolaev</surname> <given-names>VO</given-names></name><name><surname>Persani</surname> <given-names>L</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>Signaling by internalized G-protein-coupled receptors</article-title><source>Trends in Pharmacological Sciences</source><volume>31</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2010.02.002</pub-id><pub-id pub-id-type="pmid">20303186</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>André</surname> <given-names>VM</given-names></name><name><surname>Yamazaki</surname> <given-names>I</given-names></name><name><surname>Wu</surname> <given-names>N</given-names></name><name><surname>Kleiman-Weiner</surname> <given-names>M</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons</article-title><source>The European Journal of Neuroscience</source><volume>27</volume><fpage>671</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06038.x</pub-id><pub-id pub-id-type="pmid">18279319</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum</article-title><source>Developmental Neuroscience</source><volume>20</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1159/000017294</pub-id><pub-id pub-id-type="pmid">9600386</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlier</surname> <given-names>Y</given-names></name><name><surname>Brabant</surname> <given-names>C</given-names></name><name><surname>Serrano</surname> <given-names>ME</given-names></name><name><surname>Lamberty</surname> <given-names>Y</given-names></name><name><surname>Tirelli</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The prototypical histamine H3 receptor inverse agonist thioperamide improves multiple aspects of memory processing in an inhibitory avoidance task</article-title><source>Behavioural Brain Research</source><volume>253</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2013.07.016</pub-id><pub-id pub-id-type="pmid">23867149</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Bohanick</surname> <given-names>JD</given-names></name><name><surname>Nishihara</surname> <given-names>M</given-names></name><name><surname>Seamans</surname> <given-names>JK</given-names></name><name><surname>Yang</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dopamine D1/5 receptor-mediated long-term potentiation of intrinsic excitability in rat prefrontal cortical neurons: ca2+-dependent intracellular signaling</article-title><source>Journal of Neurophysiology</source><volume>97</volume><fpage>2448</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1152/jn.00317.2006</pub-id><pub-id pub-id-type="pmid">17229830</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>JY</given-names></name><name><surname>Wang</surname> <given-names>EA</given-names></name><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility</article-title><source>Frontiers in Neuroscience</source><volume>7</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2013.00114</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>TW</given-names></name><name><surname>Wardill</surname> <given-names>TJ</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Pulver</surname> <given-names>SR</given-names></name><name><surname>Renninger</surname> <given-names>SL</given-names></name><name><surname>Baohan</surname> <given-names>A</given-names></name><name><surname>Schreiter</surname> <given-names>ER</given-names></name><name><surname>Kerr</surname> <given-names>RA</given-names></name><name><surname>Orger</surname> <given-names>MB</given-names></name><name><surname>Jayaraman</surname> <given-names>V</given-names></name><name><surname>Looger</surname> <given-names>LL</given-names></name><name><surname>Svoboda</surname> <given-names>K</given-names></name><name><surname>Kim</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Ultrasensitive fluorescent proteins for imaging neuronal activity</article-title><source>Nature</source><volume>499</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/nature12354</pub-id><pub-id pub-id-type="pmid">23868258</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dau</surname> <given-names>A</given-names></name><name><surname>Gladding</surname> <given-names>CM</given-names></name><name><surname>Sepers</surname> <given-names>MD</given-names></name><name><surname>Raymond</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice</article-title><source>Neurobiology of Disease</source><volume>62</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.11.013</pub-id><pub-id pub-id-type="pmid">24269729</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Yebenes</surname> <given-names>JG</given-names></name><name><surname>Landwehrmeyer</surname> <given-names>B</given-names></name><name><surname>Squitieri</surname> <given-names>F</given-names></name><name><surname>Reilmann</surname> <given-names>R</given-names></name><name><surname>Rosser</surname> <given-names>A</given-names></name><name><surname>Barker</surname> <given-names>RA</given-names></name><name><surname>Saft</surname> <given-names>C</given-names></name><name><surname>Magnet</surname> <given-names>MK</given-names></name><name><surname>Sword</surname> <given-names>A</given-names></name><name><surname>Rembratt</surname> <given-names>A</given-names></name><name><surname>Tedroff</surname> <given-names>J</given-names></name><collab>MermaiHD study investigators</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</article-title><source>The Lancet Neurology</source><volume>10</volume><fpage>1049</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70233-2</pub-id><pub-id pub-id-type="pmid">22071279</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellender</surname> <given-names>TJ</given-names></name><name><surname>Huerta-Ocampo</surname> <given-names>I</given-names></name><name><surname>Deisseroth</surname> <given-names>K</given-names></name><name><surname>Capogna</surname> <given-names>M</given-names></name><name><surname>Bolam</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>15340</fpage><lpage>15351</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3144-11.2011</pub-id><pub-id pub-id-type="pmid">22031880</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Gladding</surname> <given-names>CM</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>LYJ</given-names></name><name><surname>Kaufman</surname> <given-names>AM</given-names></name><name><surname>Milnerwood</surname> <given-names>AJ</given-names></name><name><surname>Raymond</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease</article-title><source>Neurobiology of Disease</source><volume>45</volume><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2011.12.019</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrada</surname> <given-names>C</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Justinova</surname> <given-names>Z</given-names></name><name><surname>Barnes</surname> <given-names>C</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Goldberg</surname> <given-names>SR</given-names></name><name><surname>Leurs</surname> <given-names>R</given-names></name><name><surname>Lluis</surname> <given-names>C</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function</article-title><source>Neuropharmacology</source><volume>55</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.05.008</pub-id><pub-id pub-id-type="pmid">18547596</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrada</surname> <given-names>C</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Bongers</surname> <given-names>G</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Leurs</surname> <given-names>R</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors</article-title><source>British Journal of Pharmacology</source><volume>157</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00152.x</pub-id><pub-id pub-id-type="pmid">19413572</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrante</surname> <given-names>RJ</given-names></name><name><surname>Kowall</surname> <given-names>NW</given-names></name><name><surname>Richardson</surname> <given-names>EP</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry</article-title><source>The Journal of Neuroscience</source><volume>11</volume><fpage>3877</fpage><lpage>3887</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.11-12-03877.1991</pub-id><pub-id pub-id-type="pmid">1836019</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Hernández</surname> <given-names>J</given-names></name><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Hernández-Echeagaray</surname> <given-names>E</given-names></name><name><surname>Calvert</surname> <given-names>CR</given-names></name><name><surname>Jokel</surname> <given-names>ES</given-names></name><name><surname>Fienberg</surname> <given-names>AA</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32</article-title><source>Journal of Neurophysiology</source><volume>88</volume><fpage>3010</fpage><lpage>3020</lpage><pub-id pub-id-type="doi">10.1152/jn.00361.2002</pub-id><pub-id pub-id-type="pmid">12466426</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname> <given-names>S</given-names></name><name><surname>Ondo</surname> <given-names>W</given-names></name><name><surname>Fahn</surname> <given-names>S</given-names></name><name><surname>Hunter</surname> <given-names>C</given-names></name><name><surname>Oakes</surname> <given-names>D</given-names></name><name><surname>Plumb</surname> <given-names>S</given-names></name><name><surname>Marshall</surname> <given-names>F</given-names></name><name><surname>Shoulson</surname> <given-names>I</given-names></name><name><surname>Eberly</surname> <given-names>S</given-names></name><name><surname>Walker</surname> <given-names>F</given-names></name><name><surname>Factor</surname> <given-names>S</given-names></name><name><surname>Hunt</surname> <given-names>V</given-names></name><name><surname>Shinaman</surname> <given-names>A</given-names></name><name><surname>Jankovic</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A study of chorea after tetrabenazine withdrawal in patients with Huntington disease</article-title><source>Clinical Neuropharmacology</source><volume>31</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3180ca77ea</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fribourg</surname> <given-names>M</given-names></name><name><surname>Moreno</surname> <given-names>JL</given-names></name><name><surname>Holloway</surname> <given-names>T</given-names></name><name><surname>Provasi</surname> <given-names>D</given-names></name><name><surname>Baki</surname> <given-names>L</given-names></name><name><surname>Mahajan</surname> <given-names>R</given-names></name><name><surname>Park</surname> <given-names>G</given-names></name><name><surname>Adney</surname> <given-names>SK</given-names></name><name><surname>Hatcher</surname> <given-names>C</given-names></name><name><surname>Eltit</surname> <given-names>JM</given-names></name><name><surname>Ruta</surname> <given-names>JD</given-names></name><name><surname>Albizu</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Umali</surname> <given-names>A</given-names></name><name><surname>Shim</surname> <given-names>J</given-names></name><name><surname>Fabiato</surname> <given-names>A</given-names></name><name><surname>MacKerell</surname> <given-names>AD</given-names></name><name><surname>Brezina</surname> <given-names>V</given-names></name><name><surname>Sealfon</surname> <given-names>SC</given-names></name><name><surname>Filizola</surname> <given-names>M</given-names></name><name><surname>González-Maeso</surname> <given-names>J</given-names></name><name><surname>Logothetis</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs</article-title><source>Cell</source><volume>147</volume><fpage>1011</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.055</pub-id><pub-id pub-id-type="pmid">22118459</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garret</surname> <given-names>C</given-names></name><name><surname>Carruette</surname> <given-names>A</given-names></name><name><surname>Fardin</surname> <given-names>V</given-names></name><name><surname>Moussaoui</surname> <given-names>S</given-names></name><name><surname>Peyronel</surname> <given-names>JF</given-names></name><name><surname>Blanchard</surname> <given-names>JC</given-names></name><name><surname>Laduron</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>RP 67580, a potent and selective substance P non-peptide antagonist]</article-title><source>Comptes Rendus De l'Academie Des Sciences. Serie III, Sciences De La Vie</source><volume>314</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">1376187</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giménez-Llort</surname> <given-names>L</given-names></name><name><surname>Martínez</surname> <given-names>E</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Different effects of dopamine antagonists on spontaneous and NMDA-induced motor activity in mice</article-title><source>Pharmacology Biochemistry and Behavior</source><volume>56</volume><fpage>549</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(96)00295-X</pub-id><pub-id pub-id-type="pmid">9077595</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginés</surname> <given-names>S</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Alberch</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Impaired TrkB-mediated ERK1/2 activation in Huntington disease knock-in striatal cells involves reduced p52/p46 shc expression</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>21537</fpage><lpage>21548</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.084202</pub-id><pub-id pub-id-type="pmid">20442398</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giralt</surname> <given-names>A</given-names></name><name><surname>Puigdellívol</surname> <given-names>M</given-names></name><name><surname>Carretón</surname> <given-names>O</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Valero</surname> <given-names>J</given-names></name><name><surname>Parra-Damas</surname> <given-names>A</given-names></name><name><surname>Saura</surname> <given-names>CA</given-names></name><name><surname>Alberch</surname> <given-names>J</given-names></name><name><surname>Ginés</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>1203</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr552</pub-id><pub-id pub-id-type="pmid">22116937</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname> <given-names>S</given-names></name><name><surname>Rangel-Barajas</surname> <given-names>C</given-names></name><name><surname>Peper</surname> <given-names>M</given-names></name><name><surname>Lorenzo</surname> <given-names>R</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Ciruela</surname> <given-names>F</given-names></name><name><surname>Borycz</surname> <given-names>J</given-names></name><name><surname>Ortiz</surname> <given-names>J</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Volkow</surname> <given-names>ND</given-names></name><name><surname>Rubinstein</surname> <given-names>M</given-names></name><name><surname>Floran</surname> <given-names>B</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain</article-title><source>Molecular Psychiatry</source><volume>17</volume><fpage>650</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.93</pub-id><pub-id pub-id-type="pmid">21844870</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname> <given-names>S</given-names></name><name><surname>Moreno-Delgado</surname> <given-names>D</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Pérez-Capote</surname> <given-names>K</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Ortiz</surname> <given-names>J</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Canela</surname> <given-names>E</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Circadian-related heteromerization of adrenergic and dopamine D₄ receptors modulates melatonin synthesis and release in the pineal gland</article-title><source>PLOS Biology</source><volume>10</volume><elocation-id>e1001347</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001347</pub-id><pub-id pub-id-type="pmid">22723743</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracia</surname> <given-names>E</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Homodimerization of Adenosine A₁ receptors in brain cortex explains the biphasic effects of caffeine</article-title><source>Neuropharmacology</source><volume>71</volume><fpage>56</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.005</pub-id><pub-id pub-id-type="pmid">23523559</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidetti</surname> <given-names>P</given-names></name><name><surname>Charles</surname> <given-names>V</given-names></name><name><surname>Chen</surname> <given-names>EY</given-names></name><name><surname>Reddy</surname> <given-names>PH</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Whetsell</surname> <given-names>WO</given-names></name><name><surname>Schwarcz</surname> <given-names>R</given-names></name><name><surname>Tagle</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production</article-title><source>Experimental Neurology</source><volume>169</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7626</pub-id><pub-id pub-id-type="pmid">11358447</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guitart</surname> <given-names>X</given-names></name><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Yano</surname> <given-names>H</given-names></name><name><surname>Cai</surname> <given-names>NS</given-names></name><name><surname>Sánchez-Soto</surname> <given-names>M</given-names></name><name><surname>Kumar-Barodia</surname> <given-names>S</given-names></name><name><surname>Naidu</surname> <given-names>YT</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor Receptor Heterotetramer</article-title><source>Molecular Pharmacology</source><volume>86</volume><fpage>417</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1124/mol.114.093096</pub-id><pub-id pub-id-type="pmid">25097189</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname> <given-names>HL</given-names></name><name><surname>Sergeeva</surname> <given-names>OA</given-names></name><name><surname>Selbach</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Histamine in the nervous system</article-title><source>Physiological Reviews</source><volume>88</volume><fpage>1183</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1152/physrev.00043.2007</pub-id><pub-id pub-id-type="pmid">18626069</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>J</given-names></name><name><surname>Janssen</surname> <given-names>WG</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Roberts</surname> <given-names>JA</given-names></name><name><surname>McKay</surname> <given-names>H</given-names></name><name><surname>Lasley</surname> <given-names>B</given-names></name><name><surname>Allen</surname> <given-names>PB</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Rapp</surname> <given-names>PR</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Hof</surname> <given-names>PR</given-names></name><name><surname>Morrison</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Estrogen increases the number of spinophilin-immunoreactive spines in the Hippocampus of young and aged female rhesus monkeys</article-title><source>The Journal of Comparative Neurology</source><volume>465</volume><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1002/cne.10837</pub-id><pub-id pub-id-type="pmid">12975814</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasbi</surname> <given-names>A</given-names></name><name><surname>Perreault</surname> <given-names>ML</given-names></name><name><surname>Shen</surname> <given-names>MY</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>To</surname> <given-names>R</given-names></name><name><surname>Fan</surname> <given-names>T</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Ji</surname> <given-names>X</given-names></name><name><surname>O'Dowd</surname> <given-names>BF</given-names></name><name><surname>George</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function <italic>in vitro</italic> and <italic>in vivo:</italic> effective selective antagonism</article-title><source>The FASEB Journal</source><volume>28</volume><fpage>4806</fpage><lpage>4820</lpage><pub-id pub-id-type="doi">10.1096/fj.14-254037</pub-id><pub-id pub-id-type="pmid">25063849</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffner</surname> <given-names>G</given-names></name><name><surname>Souès</surname> <given-names>S</given-names></name><name><surname>Djian</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Aggregation of expanded huntingtin in the brains of patients with Huntington disease</article-title><source>Prion</source><volume>1</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.4161/pri.1.1.4056</pub-id><pub-id pub-id-type="pmid">19172113</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Huntington Study Group</collab></person-group><year iso-8601-date="2006">2006</year><article-title>Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial</article-title><source>Neurology</source><volume>66</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000198586.85250.13</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakel</surname> <given-names>RJ</given-names></name><name><surname>Maragos</surname> <given-names>WF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neuronal cell death in Huntington's disease: a potential role for dopamine</article-title><source>Trends in Neurosciences</source><volume>23</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(00)01568-X</pub-id><pub-id pub-id-type="pmid">10838590</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jose</surname> <given-names>PA</given-names></name><name><surname>Yu</surname> <given-names>PY</given-names></name><name><surname>Yamaguchi</surname> <given-names>I</given-names></name><name><surname>Eisner</surname> <given-names>GM</given-names></name><name><surname>Mouradian</surname> <given-names>MM</given-names></name><name><surname>Felder</surname> <given-names>CC</given-names></name><name><surname>Felder</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Dopamine D1 receptor regulation of phospholipase C</article-title><source>Hypertension Research</source><volume>18 Suppl 1</volume><fpage>S39</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1291/hypres.18.SupplementI_S39</pub-id><pub-id pub-id-type="pmid">8529072</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname> <given-names>A</given-names></name><name><surname>Albarran-Zeckler</surname> <given-names>R</given-names></name><name><surname>Walsh</surname> <given-names>HE</given-names></name><name><surname>Smith</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism</article-title><source>Neuron</source><volume>73</volume><fpage>317</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.10.038</pub-id><pub-id pub-id-type="pmid">22284186</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komater</surname> <given-names>VA</given-names></name><name><surname>Buckley</surname> <given-names>MJ</given-names></name><name><surname>Browman</surname> <given-names>KE</given-names></name><name><surname>Pan</surname> <given-names>JB</given-names></name><name><surname>Hancock</surname> <given-names>AA</given-names></name><name><surname>Decker</surname> <given-names>MW</given-names></name><name><surname>Fox</surname> <given-names>GB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effects of histamine H3 receptor antagonists in two models of spatial learning</article-title><source>Behavioural Brain Research</source><volume>159</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2004.11.008</pub-id><pub-id pub-id-type="pmid">15817192</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kononoff Vanhanen</surname> <given-names>J</given-names></name><name><surname>Nuutinen</surname> <given-names>S</given-names></name><name><surname>Tuominen</surname> <given-names>M</given-names></name><name><surname>Panula</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histamine H3 receptor regulates sensorimotor gating and dopaminergic signaling in the striatum</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>357</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1124/jpet.115.230771</pub-id><pub-id pub-id-type="pmid">26945087</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotowski</surname> <given-names>SJ</given-names></name><name><surname>Hopf</surname> <given-names>FW</given-names></name><name><surname>Seif</surname> <given-names>T</given-names></name><name><surname>Bonci</surname> <given-names>A</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endocytosis promotes rapid dopaminergic signaling</article-title><source>Neuron</source><volume>71</volume><fpage>278</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.05.036</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname> <given-names>AC</given-names></name><name><surname>Malenka</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models</article-title><source>Nature</source><volume>445</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1038/nature05506</pub-id><pub-id pub-id-type="pmid">17287809</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>AD</given-names></name><name><surname>Watkins</surname> <given-names>LH</given-names></name><name><surname>Sahakian</surname> <given-names>BJ</given-names></name><name><surname>Hodges</surname> <given-names>JR</given-names></name><name><surname>Robbins</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits</article-title><source>Brain</source><volume>123 ( Pt 7</volume><fpage>1349</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1093/brain/123.7.1349</pub-id><pub-id pub-id-type="pmid">10869048</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>LT</given-names></name><name><surname>Ng</surname> <given-names>SY</given-names></name><name><surname>Chu</surname> <given-names>JY</given-names></name><name><surname>Sekar</surname> <given-names>R</given-names></name><name><surname>Harikumar</surname> <given-names>KG</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Chow</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Transmembrane peptides as unique tools to demonstrate the <italic>in vivo</italic> action of a cross‐class GPCR heterocomplex</article-title><source>FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology</source><volume>28</volume><fpage>2632</fpage><lpage>2644</lpage><pub-id pub-id-type="doi">10.1096/fj.13-246868</pub-id><pub-id pub-id-type="pmid">24599969</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemiere</surname> <given-names>J</given-names></name><name><surname>Decruyenaere</surname> <given-names>M</given-names></name><name><surname>Evers-Kiebooms</surname> <given-names>G</given-names></name><name><surname>Vandenbussche</surname> <given-names>E</given-names></name><name><surname>Dom</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study</article-title><source>Journal of Neurology</source><volume>251</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1007/s00415-004-0461-9</pub-id><pub-id pub-id-type="pmid">15316797</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname> <given-names>R</given-names></name><name><surname>Goldman-Rakic</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Segregation of working memory functions within the dorsolateral prefrontal cortex</article-title><source>Experimental Brain Research</source><volume>133</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s002210000397</pub-id><pub-id pub-id-type="pmid">10933207</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloret</surname> <given-names>A</given-names></name><name><surname>Dragileva</surname> <given-names>E</given-names></name><name><surname>Teed</surname> <given-names>A</given-names></name><name><surname>Espinola</surname> <given-names>J</given-names></name><name><surname>Fossale</surname> <given-names>E</given-names></name><name><surname>Gillis</surname> <given-names>T</given-names></name><name><surname>Lopez</surname> <given-names>E</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name><name><surname>MacDonald</surname> <given-names>ME</given-names></name><name><surname>Wheeler</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>2015</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl125</pub-id><pub-id pub-id-type="pmid">16687439</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Calebiro</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cell biology: receptor signals come in waves</article-title><source>Nature</source><volume>495</volume><fpage>457</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nature12086</pub-id><pub-id pub-id-type="pmid">23515157</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López de Maturana</surname> <given-names>R</given-names></name><name><surname>Sánchez-Pernaute</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of corticostriatal synaptic plasticity by G protein-coupled receptors</article-title><source>CNS &amp; Neurological Disorders Drug Targets</source><volume>9</volume><fpage>601</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.2174/187152710793361531</pub-id><pub-id pub-id-type="pmid">20632967</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>G</given-names></name><name><surname>Kramar</surname> <given-names>EA</given-names></name><name><surname>Rex</surname> <given-names>CS</given-names></name><name><surname>Jia</surname> <given-names>Y</given-names></name><name><surname>Chappas</surname> <given-names>D</given-names></name><name><surname>Gall</surname> <given-names>CM</given-names></name><name><surname>Simmons</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>4424</fpage><lpage>4434</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5113-06.2007</pub-id><pub-id pub-id-type="pmid">17442827</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes</article-title><source>Cell</source><volume>72</volume><fpage>971</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90585-E</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangiarini</surname> <given-names>L</given-names></name><name><surname>Sathasivam</surname> <given-names>K</given-names></name><name><surname>Seller</surname> <given-names>M</given-names></name><name><surname>Cozens</surname> <given-names>B</given-names></name><name><surname>Harper</surname> <given-names>A</given-names></name><name><surname>Hetherington</surname> <given-names>C</given-names></name><name><surname>Lawton</surname> <given-names>M</given-names></name><name><surname>Trottier</surname> <given-names>Y</given-names></name><name><surname>Lehrach</surname> <given-names>H</given-names></name><name><surname>Davies</surname> <given-names>SW</given-names></name><name><surname>Bates</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice</article-title><source>Cell</source><volume>87</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81369-0</pub-id><pub-id pub-id-type="pmid">8898202</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattay</surname> <given-names>VS</given-names></name><name><surname>Goldberg</surname> <given-names>TE</given-names></name><name><surname>Fera</surname> <given-names>F</given-names></name><name><surname>Hariri</surname> <given-names>AR</given-names></name><name><surname>Tessitore</surname> <given-names>A</given-names></name><name><surname>Egan</surname> <given-names>MF</given-names></name><name><surname>Kolachana</surname> <given-names>B</given-names></name><name><surname>Callicott</surname> <given-names>JH</given-names></name><name><surname>Weinberger</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine</article-title><source>PNAS</source><volume>100</volume><fpage>6186</fpage><lpage>6191</lpage><pub-id pub-id-type="doi">10.1073/pnas.0931309100</pub-id><pub-id pub-id-type="pmid">12716966</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestre</surname> <given-names>T</given-names></name><name><surname>Ferreira</surname> <given-names>J</given-names></name><name><surname>Coelho</surname> <given-names>MM</given-names></name><name><surname>Rosa</surname> <given-names>M</given-names></name><name><surname>Sampaio</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Therapeutic interventions for symptomatic treatment in Huntington's disease</article-title><source>Cochrane. Database. Syst. Rev.CD</source><volume>8</volume><elocation-id>CD006456</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD006456</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milnerwood</surname> <given-names>AJ</given-names></name><name><surname>Cummings</surname> <given-names>DM</given-names></name><name><surname>Dallérac</surname> <given-names>GM</given-names></name><name><surname>Brown</surname> <given-names>JY</given-names></name><name><surname>Vatsavayai</surname> <given-names>SC</given-names></name><name><surname>Hirst</surname> <given-names>MC</given-names></name><name><surname>Rezaie</surname> <given-names>P</given-names></name><name><surname>Murphy</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>1690</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl092</pub-id><pub-id pub-id-type="pmid">16600988</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochel</surname> <given-names>F</given-names></name><name><surname>Durant</surname> <given-names>B</given-names></name><name><surname>Durr</surname> <given-names>A</given-names></name><name><surname>Schiffmann</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e18336</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018336</pub-id><pub-id pub-id-type="pmid">21483838</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohsen</surname> <given-names>A</given-names></name><name><surname>Yoshikawa</surname> <given-names>T</given-names></name><name><surname>Miura</surname> <given-names>Y</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Naganuma</surname> <given-names>F</given-names></name><name><surname>Shibuya</surname> <given-names>K</given-names></name><name><surname>Iida</surname> <given-names>T</given-names></name><name><surname>Harada</surname> <given-names>R</given-names></name><name><surname>Okamura</surname> <given-names>N</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name><name><surname>Yanai</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanism of the histamine H(3) receptor-mediated increase in exploratory locomotor activity and anxiety-like behaviours in mice</article-title><source>Neuropharmacology</source><volume>81</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.02.003</pub-id><pub-id pub-id-type="pmid">24530460</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Hoffmann</surname> <given-names>H</given-names></name><name><surname>Gonzalez-Sepúlveda</surname> <given-names>M</given-names></name><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Vignes</surname> <given-names>M</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Moratalla</surname> <given-names>R</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Ortiz</surname> <given-names>J</given-names></name><name><surname>Franco</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>5846</fpage><lpage>5854</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.161489</pub-id><pub-id pub-id-type="pmid">21173143</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Moreno-Delgado</surname> <given-names>D</given-names></name><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Hoffmann</surname> <given-names>HM</given-names></name><name><surname>Fuentes</surname> <given-names>S</given-names></name><name><surname>Rosell-Vilar</surname> <given-names>S</given-names></name><name><surname>Gasperini</surname> <given-names>P</given-names></name><name><surname>Rodríguez-Ruiz</surname> <given-names>M</given-names></name><name><surname>Medrano</surname> <given-names>M</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>Ortiz</surname> <given-names>J</given-names></name><name><surname>Canela</surname> <given-names>E</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-d1-h3 receptor complexes as key targets for reducing cocaine's effects</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>3545</fpage><lpage>3558</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4147-13.2014</pub-id><pub-id pub-id-type="pmid">24599455</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname> <given-names>M</given-names></name><name><surname>Leavitt</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Iron dysregulation in Huntington's disease</article-title><source>Journal of Neurochemistry</source><volume>130</volume><fpage>328</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1111/jnc.12739</pub-id><pub-id pub-id-type="pmid">24717009</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Quiroz</surname> <given-names>C</given-names></name><name><surname>Moreno-Delgado</surname> <given-names>D</given-names></name><name><surname>Sierakowiak</surname> <given-names>A</given-names></name><name><surname>McDowell</surname> <given-names>K</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Rea</surname> <given-names>W</given-names></name><name><surname>Cai</surname> <given-names>NS</given-names></name><name><surname>Aguinaga</surname> <given-names>D</given-names></name><name><surname>Howell</surname> <given-names>LA</given-names></name><name><surname>Hausch</surname> <given-names>F</given-names></name><name><surname>Cortés</surname> <given-names>A</given-names></name><name><surname>Mallol</surname> <given-names>J</given-names></name><name><surname>Casadó</surname> <given-names>V</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>Ferré</surname> <given-names>S</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine</article-title><source>Journal of Neuroscience</source><volume>35</volume><fpage>6639</fpage><lpage>6653</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4364-14.2015</pub-id><pub-id pub-id-type="pmid">25926444</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orsetti</surname> <given-names>M</given-names></name><name><surname>Ferretti</surname> <given-names>C</given-names></name><name><surname>Gamalero</surname> <given-names>R</given-names></name><name><surname>Ghi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory</article-title><source>Psychopharmacology</source><volume>159</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s002130100892</pub-id><pub-id pub-id-type="pmid">11862340</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panula</surname> <given-names>P</given-names></name><name><surname>Nuutinen</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The histaminergic network in the brain: basic organization and role in disease</article-title><source>Nature Reviews. Neuroscience</source><volume>14</volume><fpage>472</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nrn3526</pub-id><pub-id pub-id-type="pmid">23783198</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Vila</surname> <given-names>I</given-names></name><name><surname>Rifé</surname> <given-names>M</given-names></name><name><surname>Lizcano</surname> <given-names>JM</given-names></name><name><surname>Alberch</surname> <given-names>J</given-names></name><name><surname>Ginés</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>10090</fpage><lpage>10101</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3237-08.2008</pub-id><pub-id pub-id-type="pmid">18829967</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascoli</surname> <given-names>V</given-names></name><name><surname>Boer-Saccomani</surname> <given-names>C</given-names></name><name><surname>Hermant</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval</article-title><source>Psychopharmacology</source><volume>202</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s00213-008-1171-2</pub-id><pub-id pub-id-type="pmid">18493749</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillot</surname> <given-names>C</given-names></name><name><surname>Heron</surname> <given-names>A</given-names></name><name><surname>Cochois</surname> <given-names>V</given-names></name><name><surname>Tardivel-Lacombe</surname> <given-names>J</given-names></name><name><surname>Ligneau</surname> <given-names>X</given-names></name><name><surname>Schwartz</surname> <given-names>JC</given-names></name><name><surname>Arrang</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain</article-title><source>Neuroscience</source><volume>114</volume><fpage>173</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00135-5</pub-id><pub-id pub-id-type="pmid">12207964</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puigdellívol</surname> <given-names>M</given-names></name><name><surname>Cherubini</surname> <given-names>M</given-names></name><name><surname>Brito</surname> <given-names>V</given-names></name><name><surname>Giralt</surname> <given-names>A</given-names></name><name><surname>Suelves</surname> <given-names>N</given-names></name><name><surname>Ballesteros</surname> <given-names>J</given-names></name><name><surname>Zamora-Moratalla</surname> <given-names>A</given-names></name><name><surname>Martín</surname> <given-names>ED</given-names></name><name><surname>Eipper</surname> <given-names>BA</given-names></name><name><surname>Alberch</surname> <given-names>J</given-names></name><name><surname>Ginés</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>7265</fpage><lpage>7285</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv426</pub-id><pub-id pub-id-type="pmid">26464483</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puigdellívol</surname> <given-names>M</given-names></name><name><surname>Saavedra</surname> <given-names>A</given-names></name><name><surname>Pérez-Navarro</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF</article-title><source>Brain Pathology</source><volume>26</volume><fpage>752</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1111/bpa.12432</pub-id><pub-id pub-id-type="pmid">27529673</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapanelli</surname> <given-names>M</given-names></name><name><surname>Frick</surname> <given-names>LR</given-names></name><name><surname>Pogorelov</surname> <given-names>V</given-names></name><name><surname>Ota</surname> <given-names>KT</given-names></name><name><surname>Abbasi</surname> <given-names>E</given-names></name><name><surname>Ohtsu</surname> <given-names>H</given-names></name><name><surname>Pittenger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of tourette syndrome</article-title><source>European Neuropsychopharmacology</source><volume>24</volume><fpage>1896</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.10.007</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapanelli</surname> <given-names>M</given-names></name><name><surname>Frick</surname> <given-names>LR</given-names></name><name><surname>Horn</surname> <given-names>KD</given-names></name><name><surname>Schwarcz</surname> <given-names>RC</given-names></name><name><surname>Pogorelov</surname> <given-names>V</given-names></name><name><surname>Nairn</surname> <given-names>AC</given-names></name><name><surname>Pittenger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The histamine H3 receptor differentially modulates Mitogen-activated protein kinase (MAPK) and akt signaling in striatonigral and striatopallidal neurons</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>21042</fpage><lpage>21052</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.731406</pub-id><pub-id pub-id-type="pmid">27510032</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname> <given-names>A</given-names></name><name><surname>Albin</surname> <given-names>RL</given-names></name><name><surname>Anderson</surname> <given-names>KD</given-names></name><name><surname>D'Amato</surname> <given-names>CJ</given-names></name><name><surname>Penney</surname> <given-names>JB</given-names></name><name><surname>Young</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Differential loss of striatal projection neurons in Huntington disease</article-title><source>PNAS</source><volume>85</volume><fpage>5733</fpage><lpage>5737</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.15.5733</pub-id><pub-id pub-id-type="pmid">2456581</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>From arousal to cognition: the integrative position of the prefrontal cortex</article-title><source>Progress in Brain Research</source><volume>126</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/S0079-6123(00)26030-5</pub-id><pub-id pub-id-type="pmid">11105663</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosas</surname> <given-names>HD</given-names></name><name><surname>Koroshetz</surname> <given-names>WJ</given-names></name><name><surname>Chen</surname> <given-names>YI</given-names></name><name><surname>Skeuse</surname> <given-names>C</given-names></name><name><surname>Vangel</surname> <given-names>M</given-names></name><name><surname>Cudkowicz</surname> <given-names>ME</given-names></name><name><surname>Caplan</surname> <given-names>K</given-names></name><name><surname>Marek</surname> <given-names>K</given-names></name><name><surname>Seidman</surname> <given-names>LJ</given-names></name><name><surname>Makris</surname> <given-names>N</given-names></name><name><surname>Jenkins</surname> <given-names>BG</given-names></name><name><surname>Goldstein</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis</article-title><source>Neurology</source><volume>60</volume><fpage>1615</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000065888.88988.6e</pub-id><pub-id pub-id-type="pmid">12771251</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>CA</given-names></name><name><surname>Tabrizi</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Huntington's disease: from molecular pathogenesis to clinical treatment</article-title><source>The Lancet Neurology</source><volume>10</volume><fpage>83</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70245-3</pub-id><pub-id pub-id-type="pmid">21163446</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname> <given-names>JH</given-names></name><name><surname>Yanai</surname> <given-names>K</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1994">1994a</year><article-title>Marked increase in histamine H3 receptors in the striatum and substantia nigra after 6-hydroxydopamine-induced denervation of dopaminergic neurons: an autoradiographic study</article-title><source>Neuroscience Letters</source><volume>178</volume><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(94)90279-8</pub-id><pub-id pub-id-type="pmid">7816330</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname> <given-names>JH</given-names></name><name><surname>Yanai</surname> <given-names>K</given-names></name><name><surname>Iwata</surname> <given-names>R</given-names></name><name><surname>Ido</surname> <given-names>T</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1994">1994b</year><article-title>Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat brain</article-title><source>NeuroReport</source><volume>5</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1097/00001756-199401000-00022</pub-id><pub-id pub-id-type="pmid">8025257</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajikumar</surname> <given-names>S</given-names></name><name><surname>Frey</surname> <given-names>JU</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Late-associativity, synaptic tagging, and the role of dopamine during LTP and LTD</article-title><source>Neurobiology of Learning and Memory</source><volume>82</volume><fpage>12</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2004.03.003</pub-id><pub-id pub-id-type="pmid">15183167</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Lemus</surname> <given-names>E</given-names></name><name><surname>Arias-Montaño</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices</article-title><source>Neuroscience Letters</source><volume>364</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.04.045</pub-id><pub-id pub-id-type="pmid">15196671</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenova</surname> <given-names>MM</given-names></name><name><surname>Mäki-Hokkonen</surname> <given-names>AM</given-names></name><name><surname>Cao</surname> <given-names>J</given-names></name><name><surname>Komarovski</surname> <given-names>V</given-names></name><name><surname>Forsberg</surname> <given-names>KM</given-names></name><name><surname>Koistinaho</surname> <given-names>M</given-names></name><name><surname>Coffey</surname> <given-names>ET</given-names></name><name><surname>Courtney</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death</article-title><source>Nature Neuroscience</source><volume>10</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/nn1869</pub-id><pub-id pub-id-type="pmid">17369826</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname> <given-names>DA</given-names></name><name><surname>Rex</surname> <given-names>CS</given-names></name><name><surname>Palmer</surname> <given-names>L</given-names></name><name><surname>Pandyarajan</surname> <given-names>V</given-names></name><name><surname>Fedulov</surname> <given-names>V</given-names></name><name><surname>Gall</surname> <given-names>CM</given-names></name><name><surname>Lynch</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice</article-title><source>PNAS</source><volume>106</volume><fpage>4906</fpage><lpage>4911</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811228106</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotrel</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>RS</given-names></name><name><surname>Kaufmann</surname> <given-names>WE</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: A quantitative Golgi study</article-title><source>Neurology</source><volume>43</volume><fpage>2088</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1212/WNL.43.10.2088</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spires</surname> <given-names>TL</given-names></name><name><surname>Grote</surname> <given-names>HE</given-names></name><name><surname>Garry</surname> <given-names>S</given-names></name><name><surname>Cordery</surname> <given-names>PM</given-names></name><name><surname>Van Dellen</surname> <given-names>A</given-names></name><name><surname>Blakemore</surname> <given-names>C</given-names></name><name><surname>Hannan</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice</article-title><source>European Journal of Neuroscience</source><volume>19</volume><fpage>2799</fpage><lpage>2807</lpage><pub-id pub-id-type="doi">10.1111/j.0953-816X.2004.03374.x</pub-id><pub-id pub-id-type="pmid">15147313</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Janssen</surname> <given-names>WG</given-names></name><name><surname>Hao</surname> <given-names>J</given-names></name><name><surname>Roberts</surname> <given-names>JA</given-names></name><name><surname>McKay</surname> <given-names>H</given-names></name><name><surname>Lasley</surname> <given-names>B</given-names></name><name><surname>Allen</surname> <given-names>PB</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Rapp</surname> <given-names>PR</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Hof</surname> <given-names>PR</given-names></name><name><surname>Morrison</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys</article-title><source>Cerebral Cortex</source><volume>14</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhg121</pub-id><pub-id pub-id-type="pmid">14704219</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>TS</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Bezprozvanny</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dopaminergic signaling and striatal neurodegeneration in Huntington's disease</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>7899</fpage><lpage>7910</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1396-07.2007</pub-id><pub-id pub-id-type="pmid">17652581</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>DM</given-names></name><name><surname>Moser</surname> <given-names>R</given-names></name><name><surname>Régulier</surname> <given-names>E</given-names></name><name><surname>Breuillaud</surname> <given-names>L</given-names></name><name><surname>Dixon</surname> <given-names>M</given-names></name><name><surname>Beesen</surname> <given-names>AA</given-names></name><name><surname>Elliston</surname> <given-names>L</given-names></name><name><surname>Silva Santos</surname> <given-names>MF</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>L</given-names></name><name><surname>Goldstein</surname> <given-names>DR</given-names></name><name><surname>Ferrante</surname> <given-names>RJ</given-names></name><name><surname>Luthi-Carter</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>2313</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4965-11.2013</pub-id><pub-id pub-id-type="pmid">23392662</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trettel</surname> <given-names>F</given-names></name><name><surname>Rigamonti</surname> <given-names>D</given-names></name><name><surname>Hilditch-Maguire</surname> <given-names>P</given-names></name><name><surname>Wheeler</surname> <given-names>VC</given-names></name><name><surname>Sharp</surname> <given-names>AH</given-names></name><name><surname>Persichetti</surname> <given-names>F</given-names></name><name><surname>Cattaneo</surname> <given-names>E</given-names></name><name><surname>MacDonald</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells</article-title><source>Human Molecular Genetics</source><volume>9</volume><fpage>2799</fpage><lpage>2809</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.19.2799</pub-id><pub-id pub-id-type="pmid">11092756</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijayraghavan</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Birnbaum</surname> <given-names>SG</given-names></name><name><surname>Williams</surname> <given-names>GV</given-names></name><name><surname>Arnsten</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory</article-title><source>Nature Neuroscience</source><volume>10</volume><fpage>376</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/nn1846</pub-id><pub-id pub-id-type="pmid">17277774</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viñals</surname> <given-names>X</given-names></name><name><surname>Moreno</surname> <given-names>E</given-names></name><name><surname>Lanfumey</surname> <given-names>L</given-names></name><name><surname>Cordomí</surname> <given-names>A</given-names></name><name><surname>Pastor</surname> <given-names>A</given-names></name><name><surname>de La Torre</surname> <given-names>R</given-names></name><name><surname>Gasperini</surname> <given-names>P</given-names></name><name><surname>Navarro</surname> <given-names>G</given-names></name><name><surname>Howell</surname> <given-names>LA</given-names></name><name><surname>Pardo</surname> <given-names>L</given-names></name><name><surname>Lluís</surname> <given-names>C</given-names></name><name><surname>Canela</surname> <given-names>EI</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Maldonado</surname> <given-names>R</given-names></name><name><surname>Robledo</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cognitive impairment induced by Delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors</article-title><source>PLOS Biology</source><volume>13</volume><elocation-id>e1002194</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002194</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonsattel</surname> <given-names>JP</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name><name><surname>Stevens</surname> <given-names>TJ</given-names></name><name><surname>Ferrante</surname> <given-names>RJ</given-names></name><name><surname>Bird</surname> <given-names>ED</given-names></name><name><surname>Richardson</surname> <given-names>EP</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Neuropathological classification of Huntington's disease</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>44</volume><fpage>559</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1097/00005072-198511000-00003</pub-id><pub-id pub-id-type="pmid">2932539</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonsattel</surname> <given-names>JP</given-names></name><name><surname>DiFiglia</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Huntington disease</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>57</volume><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1097/00005072-199805000-00001</pub-id><pub-id pub-id-type="pmid">9596408</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Tang</surname> <given-names>TS</given-names></name><name><surname>Bezprozvanny</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tetrabenazine is neuroprotective in Huntington's disease mice</article-title><source>Molecular Neurodegeneration</source><volume>5</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/1750-1326-5-18</pub-id><pub-id pub-id-type="pmid">20420689</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>JQ</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>QC</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Cheng</surname> <given-names>HP</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Tang</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>3070</fpage><lpage>3084</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.407726</pub-id><pub-id pub-id-type="pmid">23250749</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittaker</surname> <given-names>DS</given-names></name><name><surname>Wang</surname> <given-names>H-B</given-names></name><name><surname>Loh</surname> <given-names>DH</given-names></name><name><surname>Cachope</surname> <given-names>R</given-names></name><name><surname>Colwell</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease</article-title><source>Pharmacology Research &amp; Perspectives</source><volume>5</volume><elocation-id>e00344</elocation-id><pub-id pub-id-type="doi">10.1002/prp2.344</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiescholleck</surname> <given-names>V</given-names></name><name><surname>Manahan-Vaughan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Antagonism of D1/D5 receptors prevents long-term depression (LTD) and learning-facilitated LTD at the perforant path-dentate gyrus synapse in freely behaving rats</article-title><source>Hippocampus</source><volume>24</volume><fpage>1615</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1002/hipo.22340</pub-id><pub-id pub-id-type="pmid">25112177</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.51093.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dötsch</surname><given-names>Volker</given-names> </name><role>Reviewer</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Hanyaloglu</surname><given-names>Aylin C</given-names></name><role>Reviewer</role><aff><institution>Imperial College London</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this paper the authors identify a hetero-dimer consisting of the dopamine D<sub>1</sub> and the histamine H<sub>3</sub> receptor as a crucial component in early stages of Huntington's disease. They show that inhibiting the histamine H<sub>3</sub> receptor prevents cell death signalling in cell culture and cognitive deficits in a mouse model. These data open a new avenue towards targeting Huntington's disease in its early stages.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Modulation of dopamine D<sub>1</sub> receptors via histamine H<sub>3</sub> receptors is a novel therapeutic target for Huntington's disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Volker Dötsch as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Aylin C Hanyaloglu (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This study by Moreno-Delgado and colleagues has identified a highly novel therapeutic target for Huntington's disease, a condition where there is even currently no drug to delay, let alone reverse this genetic condition. GPCR heteromers are an under-exploited therapeutic target, in part because of studies to demonstrate their direct in vivo functions, and their role in human disease have been limited. This study presents an incredible array of approaches to rigorously provide such evidence from in vitro, to in vivo HD animal models, including the existence of these heteromers in post-mortem patient samples. A critical and unique finding of the authors is that timing is critical for a therapeutic window in targeting these complexes.</p><p>Essential revisions:</p><p>1) One point that was discussed among the reviewers is the mechanism of heterodimer regulation by internalization and the distribution of the heterodimers. The distribution seen in the PLA assays show spots of the heterodimer instead of a wide distribution as one would expect from a protein in the plasma membrane. It is not clear if this distribution detects internalized receptors. Can internalization in cell culture be inhibited to show that the PLA assays detect heterodimers on the plasma membrane? Or, can the D<sub>1</sub>R-H<sub>3</sub>R heteromers expressed in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells be detected with non-permeabilized condition (Figure 1)? In Figure 3, is anything known about the mechanisms underlying the decoupling of D1-H3 heterodimers in Hdh<sup>Q7/Q111</sup> mutant mice?</p><p>2) It is suggested by the authors that activation of D<sub>1</sub>R with high concentrations of ligand induces internalization and disrupts the heteromer interaction with H<sub>3</sub>R. This may be the case as the paper cited Kotowski et al., 2011, do suggest that only very high ligand concentrations would induce receptor internalization to activate G protein signalling from an endosomal compartment, however, the data presented in Supplementary Figure 5A do not support that D<sub>1</sub>R undergoes internalization in their STHdh cells, as under basal conditions the receptor seems already vesicular/endosomal. This data that heteromer disruption is due to D<sub>1</sub>R internalization should be removed from Results/Discussion and should rather be discussed as a potential mechanism in the Discussion section.</p><p>3) The authors include nice controls in their in vitro systems for the H<sub>3</sub>R antibody. They should provide the same for the D<sub>1</sub>R antibody, or a reference if performed by the group in previous studies.</p><p>4) If higher concentrations of thioperamide are necessary for the crosstalk, please discuss the potential limitation of such strategy in therapeutic purpose.</p><p>5) In the second paragraph of the Discussion, it is suggested that more than one H<sub>3</sub>R ligand was used in the study, however, only data with thioperamide are presented. There is a mention, in the fourth paragraph of the Discussion, of an alternate H<sub>3</sub>R antagonist, VUF5681, and in the figure legend of Figure 4—figure supplement 1, but no data with VUF5681 in Figure 4—figure supplement 1. If the authors have these data it should be included to support selectivity of the thioperamide data to H<sub>3</sub>R. Similarly, thioperamide is also an antagonist of the H<sub>4</sub> receptor. Can the authors exclude effects of inhibiting the H<sub>4</sub> receptor?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.51093.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) One point that was discussed among the reviewers is the mechanism of heterodimer regulation by internalization and the distribution of the heterodimers. The distribution seen in the PLA assays show spots of the heterodimer instead of a wide distribution as one would expect from a protein in the plasma membrane. It is not clear if this distribution detects internalized receptors. Can internalization in cell culture be inhibited to show that the PLA assays detect heterodimers on the plasma membrane? Or, can the D<sub>1</sub>R-H<sub>3</sub>R heteromers expressed in STHdh<sup>Q7</sup> and STHdh<sup>Q111</sup> cells be detected with non-permeabilized condition (Figure 1)? In Figure 3, is anything known about the mechanisms underlying the decoupling of D1-H3 heterodimers in Hdh<sup>Q7/Q111</sup> mutant mice?</p></disp-quote><p>The cellular distribution pattern of PLAs is a problem that plagues this technique as judged by the literature (Borroto-Escuela et al. Mol Neurobiol. 2018; 55(8): 7038–7048. doi: 10.1007/s12035-018-0887-1 1 and Sebastianutto, I. et al. J Clin Invest 130, (2020) doi: 10.1172/JCI126361.) and in our own experience (Vinals et al., 2015 and Moreno et al. Neuropsychopharmacology 2017). In general, and due to the way the fluorescent signal is produced, PLA, are always puncta and so it is hard to judge if complexes are membrane or internal using this technique. We have only used the PLA as a tool, similar to co-immunoprecipitation (sans detergent) to demonstrate that these receptors can form a complex in vitro and ex vivo. Unfortunately, the epitopes of these antibodies are both intracellular so, permeabilization is required for these antibodies to work.</p><p>Currently, we do not understand what regulates D1-H3 heterodimers and why they would be lost in the Hdh<sup>Q7/Q111</sup> mice. Now that we have made this discovery and understood that timing is crucial we would like to follow this up in future work.</p><disp-quote content-type="editor-comment"><p>2) It is suggested by the authors that activation of D<sub>1</sub>R with high concentrations of ligand induces internalization and disrupts the heteromer interaction with H<sub>3</sub>R. This may be the case as the paper cited Kotowski et al., 2011, do suggest that only very high ligand concentrations would induce receptor internalization to activate G protein signalling from an endosomal compartment, however, the data presented in Supplementary Figure 5A do not support that D<sub>1</sub>R undergoes internalization in their STHdh cells, as under basal conditions the receptor seems already vesicular/endosomal. This data that heteromer disruption is due to D<sub>1</sub>R internalization should be removed from Results/Discussion and should rather be discussed as a potential mechanism in the Discussion section.</p></disp-quote><p>In light of the comments above and the comments here we have decided to remove any data about trafficking and simply discuss this as a potential mechanism in the Discussion section. We have pointed out potential mechanisms of what might control dimer formation, and mentioned trafficking as one option to be pursued (Discussion).</p><disp-quote content-type="editor-comment"><p>3) The authors include nice controls in their in vitro systems for the H<sub>3</sub>R antibody. They should provide the same for the D<sub>1</sub>R antibody, or a reference if performed by the group in previous studies.</p></disp-quote><p>The antibody used for D<sub>1</sub>R has been used by us and tested extensively in three previous publications (Rodríguez-Ruiz et al., 2016, Moreno et al., 2011 and 2014). In addition, it is from one of the most reputable GPCR antibody companies (Frontier Institute) where it was validated in knock-out animals.</p><disp-quote content-type="editor-comment"><p>4) If higher concentrations of thioperamide are necessary for the crosstalk, please discuss the potential limitation of such strategy in therapeutic purpose.</p></disp-quote><p>In this study we have focused on the target of D<sub>1</sub>R-H<sub>3</sub>R for treating Huntington’s disease and the fact that timing is crucial. We chose thioperamide for the in vivo experiments as there was a large body of literature at the time on the ADME of this compound that allowed for a more cost effective preliminary animal study to demonstrate the effectiveness of the target. Going forward, more effective compounds would need to be identified that are either more potent or more targeted to the D<sub>1</sub>R-H<sub>3</sub>R complex. Regardless, this study highlights that this complex offers and early intervention strategy to slow progression, something that might be attractive in conjunction with current gene therapy trials going forward.</p><disp-quote content-type="editor-comment"><p>5) In the second paragraph of the Discussion, it is suggested that more than one H<sub>3</sub>R ligand was used in the study, however, only data with thioperamide are presented. There is a mention, in the fourth paragraph of the Discussion, of an alternate H<sub>3</sub>R antagonist, VUF5681, and in the figure legend of Figure 4—figure supplement 1, but no data with VUF5681 in Figure 4—figure supplement 1. If the authors have these data it should be included to support selectivity of the thioperamide data to H<sub>3</sub>R.</p></disp-quote><p>We have included our data on VUF5681 showing that it also can revert D<sub>1</sub> induced cell death in 5 months brain slices (new Figure 4—figure supplement 1). In addition, we have included a discussion on what we believe H<sub>4</sub> is not involved for the observed effects. To summarize, in cells silenced of H<sub>3</sub>R or when D<sub>1</sub>R-H<sub>3</sub>R heteromers are lost in the mice (6-8 months of age). we lose any effects of thioperamide.</p><disp-quote content-type="editor-comment"><p>Similarly, thioperamide is also an antagonist of the H<sub>4</sub> receptor. Can the authors exclude effects of inhibiting the H<sub>4</sub> receptor?</p></disp-quote><p>While we cannot rule out the effects of inhibiting H<sub>4</sub>R by using thioperamide, it is important to notice that H<sub>4</sub>R expression is higher in peripheral tissues, whereas H<sub>3</sub>R is abundantly expressed in the brain (De Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H<sub>4</sub> receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26: 462–469, 2005., and Haas, Sergeeva and Selbach, 2008) and we have used brain slices to show the protection afforded by thioperamide treatment. Moreover, we found that thioperamide treatment prevented cognitive and motor learning deficits as well as the loss of heteromer expression in different brain areas of the HD mouse brain, supporting a majority role for H<sub>3</sub>R. Finally, in the experiments with 8 months old animals where there is no D1-H3 heteromer and there is no effect of thioperamide, we have every reason to believe H<sub>4</sub>R expression would remain and yet thioperamide has no effect.</p></body></sub-article></article>